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Open access under CC BV-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-speciﬁc protein kinase
that is mutated with high frequency in cutaneous melanoma, and many other cancers. Inhibition of
mutant BRAF is an attractive therapeutic approach for the treatment of melanoma. A triarylimidazole
BRAF inhibitor bearing a phenylpyrazole group (dimethyl-[2-(4-{5-[4-(1H-pyrazol-3-yl)-phenyl]-4-pyri-
din-4-yl-1H-imidazol-2-yl}-phenoxy)-ethyl]-amine, 1a) was identiﬁed as an active BRAF inhibitor. Based
on this starting point, we synthesized a series of analogues leading to the discovery of 6-{2-[4-(4-methyl-
piperazin-1-yl)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-2,4-dihydro-indeno[1,2-c]pyrazole (1j), with
nanomolar activity in three assays: inhibition of puriﬁed mutant BRAF activity in vitro; inhibition of
oncogenic BRAF-driven extracellular regulated kinase (ERK) activation in BRAF mutant melanoma cell
lines; and inhibition of proliferation in these cells.
 2010 Elsevier Ltd. Open access under CC BY license.1. Introduction (V600E).2 In cancer cells, V600EBRAF stimulates constitutive ERKThe RAS-RAF-MEK-ERK pathway is hyper-activated in approxi-
mately 30% of human cancers,1 where it stimulates cell growth and
survival. This hyper-activation is caused in part by mutations in
receptor tyrosine kinases, the small G-proteins of the RAS family,
and the serine/threonine speciﬁc protein kinase BRAF. Mutations
in BRAF (one of the three rapidly growing ﬁbrosarcoma (RAF) genes
in humans; the other two being ARAF and CRAF) occur in 2% of
human cancers, and are particularly prevalent in cutaneous mela-
nomas (50% of cases). The most common mutation (90% fre-
quency) is a glutamic acid for valine substitution at position 600-RAF murine sarcoma viral
F, dimethylformamide; ERK,
vated protein kinase; MEK,
rmacokinetics; RAF, rapidly
tionship; TFA, triﬂuoroacetic
x: +44 20 8722 4046.
ringer).
Y license.activity and drives proliferation and survival, thereby providing
essential tumor growth and maintenance functions.3 V600EBRAF
also contributes to neoangiogenesis by stimulating vascular endo-
thelial growth factor secretion.4 Consequently, BRAF is an attrac-
tive validated therapeutic target in melanoma, and several BRAF
inhibitors are currently under development and in clinical trials5
and we have previously described type II BRAF inhibitors, targeting
the inactive conformation of BRAF.6,7
Triarylimidazoles have been reported as inhibitor scaffolds for
targeting the active kinase conformation kinase, for example
p388 and RAF.9,10 The general structure of these latter kinase inhib-
itors contains a hinge-binding group, usually pyridine or pyrimi-
dine (‘ring A’), a central imidazole scaffold occupying the ribose
position in the ATP-binding pocket (‘ring C’) and a substituted aro-
matic group interacting with the hydrophobic pocket (BPII accord-
ing to Liao’s nomenclature)11 next to the gatekeeper residue (‘ring
B’) (Fig 1). The third aryl ring (‘ring D’) extends outside the ATP
pocket towards the solvent. The co-crystal structure of BRAF with
SB590885, a triarylimidazole BRAF inhibitor, indicates binding to
Figure 1. Examples of triarylimidazole BRAF inhibitors and their putative binding mode.
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ing mode.9 Therefore, these compounds are BRAF type I inhibitors.
Two examples of reported active triarylimidazole BRAF inhibitors,
L-779450 and SB-590885, are also shown in Figure 1.12,9 These
BRAF inhibitors contain an H-bond donor on ‘ring B’ (phenol or
oxime, Fig. 1) that is essential for activity.
In order fully to exploit the BPII pocket of the active BRAF
conformation, we designed novel type I BRAF inhibitors based on
this scaffold, but with an H-bond donor pyrazole heterocycle
substituent on ‘ring B’, as a potential functional bioisostere of ind-
anoneoxime and chlorophenol. 4-(3-Pyrazolyl)phenyl ring B was
proposed to target the BPII pocket of BRAF and consequently com-
pound 1a was synthesized (Fig. 2). Docking of this compound with
the BRAF structure in the active conformation (pdb code 2FB8)
showed the expected orientation of the compound, similar to
SB590885, with the pyridyl ring A interacting with the hinge and
the 4-(3-pyrazolyl)phenyl ring B occupying the BPII pocket
(Fig. 2). The geometry of the oxime in indanoneoxime inhibitorsFigure 2. Structure of phenylpyrazole hiis dependent of the rest of the inhibitor: the co-crystal structure
of BRAF with an indanoneoxime BRAF inhibitor with a pyrazole
scaffold shows the oxime in E-geometry (pdb code 3D4Q),13
whereas SB590885 co-crystallises in an opposite Z-orientation.
Pleasingly, this compound was found to inhibit isolated full length
V600EBRAF at low micromolar concentrations (IC50 BRAF = 1.6 lM)
and also to inhibit V600EBRAF signalling in melanoma cells (GI50
SRB = 7.4 lM). Hit 1a was therefore used as starting point for the
structure–activity relationship (SAR) exploration and structure
optimization for new BRAF inhibitors.2. Results and discussion
2.1. Chemistry
Two synthetic routes were designed to access the desired tri-
substituted imidazoles:t 1a, and docking in BRAF structure.
6936 D. Niculescu-Duvaz et al. / Bioorg. Med. Chem. 18 (2010) 6934–6952(A) Starting from the 2,4,5-tribromo-imidazole core, 2, and
introducing the desired substituents in sequence (Scheme 1).
(B) Using the protected indanone oxime (ring B) and building
the trisubstituted imidazole core (Scheme 2).
In the ﬁrst approach, the 2,4,5-tribromo-imidazole was
protected as a methoxymethyl (MOM) derivative 3, and converted
using a two-step procedure to the 2-(4-dimethylaminoethoxyphe-
nyl)-4,5-dibromoimidazole, 5. The Suzuki coupling of this interme-
diate with 1 equiv of 4-pyridylboronic acid led to the key
intermediate 6. A second Suzuki coupling with 4-methoxybenzyl-
protected boronic acids 26, 29a–b, 37, 40 or 43 (see Schemes 5
and 6) followed by acidic deprotection of the MOM and 4-
methoxybenzyl groups generated the ﬁnal compounds 1a–c,Scheme 1. Synthesis of triarylimidazole pyrazoles by route A. Reagents and conditions: (
(iii) Cl(CH2)2N(CH3)2, Cs2CO3, DMF, 40 C; (iv) pyridyl boronic ester, K2CO3, Pd(OAc)2, PPh
5 M HCl, 60 C; (vii) TFA, 130 C.1e–g. MOM deprotection of intermediate 6 led to imidazole 7,
which could be coupled directly with boronic acid 33, to afford
compound 1d after 4-methoxybenzyl removal (Scheme 1).
The alternative route (B) is a modiﬁcation of the synthesis re-
ported by Takle et al.10 The starting material 5-bromo-2,3-dihy-
dro-1H-inden-1-one O-methyl oxime 10, was converted to the
corresponding aldehyde 11 with nBuLi and (dimethylformamide)
DMF, followed by coupling with 4-pyridylmethyleneoxy-t-butyldi-
methylsilane to afford intermediate 12. After deprotection with
tetrabutylammonium ﬂuoride, the corresponding diol, 13, was sub-
mitted to a Swern oxidation affording the dione 14. The coupling of
14 with selected aldehydes afforded the imidazole core linked to a
suitable ring D. The ﬁnal deprotection of the N-methyl indanone
oxime system yielded the ketones 16a–c, which were converted ini) MOMBr, NaH, THF; (ii) 4-HOC6H4B(OH)2, K2CO3, Pd(PPh3)4, toluene, MeOH, reﬂux;
3, DME, H2O, 90 C; (v) boronic esters, K2CO3, Pd(OAC)2, PPh3, DME, H2O, 110 C; (vi)
Scheme 2. Synthesis of triarylimidazole tricyclic pyrazoles by route B. Reagents: (i) nBuLi, THF, DMF; (ii) 4-pyridyl-CH2OTBDMS, LDA, THF; (iii) TBAF, THF; (iv) oxalyl
chloride, DMSO, Et3N, DMF; (v) RCHO, AcOH, AcONH4; (vi) 5 M HCl, dioxane; (vii) HC(NMe2)3, DMF; (viii) AcOH, H2NNH2.
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dimethylamino-methane and hydrazine (see Scheme 2).
The triazole ﬁnal compound 1i was obtained from intermediate
16b by nitrosation followed by the addition of hydrazine
(Scheme 3).
Diarylfurans with aliphatic, aromatic or carboxamide solubilis-
ing groups were previously shown to be alternative scaffolds for
the synthesis of BRAF inhibitors.14 Consequently, we synthesized
several furan analogues with our most active tricyclic pyrazole ring
B. For the synthesis of the trisubstituted furan analogues, the start-
ing material was methyl-2,3-dibromofuran-5-yl carboxylate 17.
Using two consecutive Suzuki couplings with 4-pyridyl boronic
acid followed by 1-(methoxyimino)-2,3-dihydro-1H-inden-5-ylbo-
ronic acid, the intermediate 19 was obtained. Basic hydrolysis of
intermediate 19 with NaOH afforded the corresponding carboxylic
acid, 20, followed by acidic hydrolysis to remove the oxime ether
group and generate the ketone 21. Condensation with the desired
amines, in the presence of diisopropylcarbodiimide, hydroxyben-zotriazole and triethylamine in DMF, produced the key intermedi-
ates 22a–d. The condensation of 22a–d with hydrazine or
methylhydrazine gave the desired ﬁnal compounds 1l–o and 1p,
respectively (Scheme 4).
Since most of the boronic acids used in the synthesis of the imi-
dazoles previously described in Scheme 1 are not commercially
available, their preparation is summarized in Schemes 5 and 6.
2.2. SAR of ring B—phenylpyrazole
In order to identify new type I BRAF inhibitors with a triarylim-
idazole scaffold, compound 1awith 4-(3-pyrazolyl)phenyl as ring B
was synthesized and found to be effective. The SAR of ring B was
explored further, leading to the discovery of the more potent
1,4-dihydroindeno[1,2-c]pyrazole. Using this group, further SAR
exploration of rings C and D was performed.
The biological activities of compounds 1a–p were assessed in
three assays:
Scheme 4. Synthesis of diarylfuranamides. Reagents: (i) 4-pyridylboronic acid, Cs2CO3, Ph3As, Pd(PPh3)Cl2, DMF; (ii) 1-(methoxyimino)-2,3-dihydro-1H-inden-5-ylboronic
acid, Cs2CO3, Ph3As, Pd(PPh3)2Cl2, DMF; (iii) NaOH, THF, MeOH; (iv) 5 M HCl, dioxane–Me2CO; (v) amine, DIC, HOBt, TEA, DMF; (vi) DMF–DMA, H2NNH2, AcOH; (vii) DMF–
DMA, MeHNNH2, AcOH; (viii) 4 N HCl.
Scheme 3. Synthesis of tricyclic triazole. Reagents and conditions: (i) tBuONO, HCl, methoxyethanol; (ii) ethylene glycol, KOH, H2NNH2, 190 C.
6938 D. Niculescu-Duvaz et al. / Bioorg. Med. Chem. 18 (2010) 6934–6952(1) Inhibition of the isolated V600EBRAF kinase activity (IC50
BRAF),measuringMEK1/2phosphorylation as the endpoint.15
AnalternativeBRAFﬂuorescent ligandbinding assay10,14 gave
much lower Kd values than the IC50s for the V600EBRAF kinase
activity (for example: compound 1h, Kd = 6.1 nM whereas
IC50 BRAF = 230 nM). We measured the IC50 BRAF values in
this paper, since they represent the inhibition of BRAF func-
tion which we consider more meaningful than the binding
of inhibitor to BRAF.(2) Inhibition of V600EBRAF-dependent ERK phosphorylation in
WM266.4 melanoma cells (IC50 pERK).
(3) Growth inhibition of WM266.4 melanoma cells measured by
sulforhodamine-B (GI50 SRB). The IC50 (BRAF), IC50 (pERK)
and GI50 (SRB) results are presented in Table 1.
Our assessment of substitution of the pyrazole ring focused on
the 4-position, since no further space is available for position 5
based on modelling studies of 1a with the BRAF structure reported
Table 1
Biological activities of BRAF inhibitors
No Compound IC50 BRAF (lM) IC50 ppERK (lM) GI50 SRB (lM)
1a 1.60 5.8 7.4
1b 1.20 2.02 3.9
1c >10 >100 11
1d 3.7 10 4.1
1e 1.84 5.8 —
1f 1.71 25 3.3
(continued on next page)
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Table 1 (continued)
No Compound IC50 BRAF (lM) IC50 ppERK (lM) GI50 SRB (lM)
1g >10 100 8.9
1h 0.23 1.09 1.15
1i >10 4.4 —
1j 0.24 0.58 0.87
1k 1.33 4.9 36
1l 3.6 0.74 1.61
1m 2.15 0.84 0.94
6940 D. Niculescu-Duvaz et al. / Bioorg. Med. Chem. 18 (2010) 6934–6952
Table 1 (continued)
No Compound IC50 BRAF (lM) IC50 ppERK (lM) GI50 SRB (lM)
1n 2.78 0.97 1.59
1o 7.5 0.73 1.91
1p >10 >10 —
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the 4-position of the pyrazole with methyl (compound 1b) is toler-
ated and beneﬁcial. Larger substituents such as cyano or chlorine
lead to loss of activity against both isolated BRAF and in cellular as-
says (1c, 1d). This effect could be due to a steric clash with the
BRAF binding pocket or an unfavourable electrostatic interaction.
In order to ﬁx the position of the pyrazole ring, more rigid tricyclic
systems were synthesized: 1e–h.
The ﬁve-membered ring (1,4-dihydroindeno[1,2-c]pyrazole 1h)
increases the potency against BRAF ﬁvefold compared to the
non-cyclic analogue 1b. This tricyclic system mimics the ind-
anoneoxime moiety, with the oxime group in the E-geometry. Sat-
urated or aromatic six-membered rings (1e, 1f) are not as effective
as the ﬁve-membered ring. Methylation of the pyrazole leads to a
loss in activity (1p vs 1l) consistent with the hypothesis that an
H-donor group is beneﬁcial for potent BRAF inhibition. Interest-
ingly, the tricyclic triazole analogue 1i is inactive, possibly due to
a polarity mismatch between the polar 3-position of the triazole
(corresponding to the 5-position of the pyrazole) and a non-polar
area of the BPII binding pocket. Similar results were observed
with the tricyclic pyridazinone 1g, where the inactivity can be
attributed to either polarity mismatch or steric clash. Since the
1,4-dihydroindeno[1,2-c]pyrazole 1h is the most active ring B,
further optimization of rings C and D were performed keeping this
ring B constant.
2.3. SAR of rings C and D
Furan-based analogues of SB-590885, where the core imidazole
ring C was replaced by furan, with a variety of solubilizing D
groups have been reported as potent BRAF inhibitors.14 We have
synthesized a number of furan-amides with our tricyclic pyrazole
‘ring B’ as BRAF inhibitors (1l–p), which were found to possess
weaker activity against BRAF than their imidazole counterparts,but surprisingly good cellular activity (for example compound
1m has submicromolar activity in both IC50 ppERK and GI50 SRB
assays).
Modiﬁcation of the substituents on the phenyl ‘group D’ (solu-
bilizing group) of the imidazole inhibitors is expected to have a
minimal effect on the BRAF potency but could modulate the cellu-
lar activity or the physicochemical properties of this series. Indeed,
the replacement of the 2-dimethylaminoethoxy side chain of ring
D (in 1h) with N-methylpiperazine lead to compound 1j, which
is equipotent on BRAF IC50 with 1h, but has improved cellular
activity. Compound 1j has submicromolar activity in all 3 assays.
Replacing the whole aryl ring D with a piperidine ring (1k) has a
negative effect on BRAF potency, with a sixfold potency loss com-
pared to 1h or 1j.
2.4. Pharmacokinetic (PK) data
The apparent clearance, half-life (t1/2) and maximal plasma con-
centration of a representative tricyclic pyrazole, compound 1h,
were determined in vivo in CD1 nu/nu female mice following an
intraperitoneal administrationof1h.This compoundexhibits a good
PK proﬁle, with a low plasma clearance (CL = 11 mL/min/kg), long
half-life (T1/2 = 3.9 h) and reaches plasma concentrations above its
SRB cellular IC50 (Cmax = 5.8 lM; IC50 (SRB) = 1.1 lM).
3. Conclusion
A triarylimidazole BRAF inhibitor bearing a phenylpyrazole
group (1a) was identiﬁed as an active BRAF inhibitor. Starting from
this lead, optimization and SAR investigations led to the identiﬁca-
tion of the more potent tricyclic 1,4-dihydroindeno[1,2-c]pyrazole
BRAF inhibitor 1h, with a favourable PK proﬁle. Replacement of the
imidazole core scaffold with furanamide led to compounds with
weaker activity against isolated mutant BRAF, but with comparable
6942 D. Niculescu-Duvaz et al. / Bioorg. Med. Chem. 18 (2010) 6934–6952cellular activity. The triarylimidazole 1j with a phenylpiperazine
ring D is the most promising compound, with nanomolar activity
in the mutant BRAF inhibition assay, the cellular pERK inhibition
and the mutant BRAF melanoma WM266.4 growth inhibition.
4. Experimental
4.1. Chemistry
4.1.1. Materials and methods
All starting materials, reagents and solvents for reactions were
reagent grade and used as purchased. Chromatography solvents
were HPLC grade and were used without further puriﬁcation. Reac-
tions were monitored by thin layer chromatography (TLC) analysis
using Merck Silica Gel 60 F-254 thin layer plates. Flash column
chromatography was carried out on Merck Silica Gel 60 (0.015–
0.040 mm) or in disposable Isolute Flash Si and Si II silica gel col-
umns. LC-MS analyseswere performed on aMicromass LCT/Water’s
Alliance 2795 HPLC system using 5 lm Atlantis C18, 50 mm  2.1
mm columns at 22 C with the following solvent system: aqueous:
water + 0.1% formic acid; organic: 0.1% formic + acetonitrile, at a
ﬂow rate of 1 mL/min. Method A: gradient starting with 100% aque-
ous to 100% organic in 2.5 min at room temperature and a ﬂow rate
of 0.6 mL/min or method B gradient starting with 100% aqueous to
100% organic in 5 min at 40 C (column temperature) at a ﬂow rate
of 0.6 mL/min. UV detection was at 215 nm and ionisation was po-
sitive or negative ion electrospray. Themolecular weight scan range
was 50–1000. Samples were injected at 3 lL on a partial loop ﬁll. All
automated HPLC puriﬁcation were performed on Gilson Prep LC
modules running on software version 1.71 or 3.0 and on Hyper-
prepHSC18 100 mm  21.2 mm columns, 12 lm, at a ﬂow rate of
30 mL/min at room temperature using as aqueous phase:
water + 0.1% (triﬂuoroacetic acid) TFA and as organic phase: aceto-
nitrile + 0.1% TFA (UV detector, at 215 and 254 nm). The purity of
the ﬁnal compounds was determined by HPLC as described above
and is 95% or higher unless speciﬁed otherwise. 1H NMR spectra
were recorded on either a 250 MHz or a 400 MHz Bruker NMR ma-
chine. Accurate Mass Measurement was performed with a Waters
Micromass LCT Premier Orthogonal Acceleration Time-of-Flight
Mass Spectrometer 4 GHz TDC with LockSpray™ enable mass mea-
surements of 5 ppm or better form/z of 400 or greater and 2 mDa or
better for m/z of 400 or less. Calibration reference: Wpos_150208.-
cal or Wneg_150208a.cal. MassLynx v4.1 SCN 633 was the operat-
ing software using the in-built elemental composition to report
data. Minimum 10 scans are combined across a MS peak.4.1.2. Synthesis and characterization of intermediates 3–9
(Scheme 1)
4.1.2.1. 2,4,5-Tribromo-1-methoxymethyl-1H-imidazole (3). Tri-
bromo imidazole 2 (6.1 g, 20.0 mmol) was dissolved in dry THF
(25 mL) and NaH (60% in mineral oil, 960 mg, 24 mmol) was added
portionwise. The solution was cooled to 0 C under nitrogen atmo-
sphere and MOMBr (3.33 g, 24.0 mmol) was added dropwise over
approximately 10 min. The reaction was stirred at room tempera-
ture for 2 h or until complete by LC/MS. The solution was diluted
with water (100 mL), extracted with EtOAc (3  25mL) and dried
(MgSO4). The solvent was removed under vacuum to yield 6.8 g of
3 as a white solid. (Yield: 97%). 1H NMR (250 MHz, CDCl3) d ppm:
5.34 (2H, s), 3.40 (3H, s). LCMS: tR = 1.87 min, 346 (M+H)+ calcd
for C5H5Br3N2O.
4.1.2.2. 4-(4,5-Dibromo-1-methoxymethyl-1H-imidazol-2-yl)-
phenol (4). 2,4,5-Tribromo-1-methoxymethyl-1H-imidazole 3
(2.0 g, 5.72 mmol), 4-hydroxyphenyl-boronic acid (0.821 g,
5.95 mmol), 2 M K2CO3 solution (6.4 mL) were suspended in a5:1 mixture of toluene/MeOH (120 mL). The suspension was stir-
red vigorously whilst de-gassing with nitrogen for 20 min.
Pd(PPh3)4 (0.658 g, 0.57 mmol) was added and the mixture was re-
ﬂuxed overnight. The reaction was cooled to room temperature, di-
luted with H2O (20 mL) and EtOAc (10 mL). The phases were
separated. The organic layer was then extracted with 1 M NaOH
(3  15 mL). Both aqueous layers were separately acidiﬁed with
1 M HCl until a white precipitate appeared (pH 6–7). The precipi-
tates were ﬁltered, washed with water, and dried under vacuum
to give a total of 0.800 g of 4 as a white solid. (Yield: 39%). 1H
NMR (250 MHz, DMSO-d6) d ppm: 7.37 (2H, d, J = 8.60 Hz), 6.70
(2H, d, J = 8.6 Hz), 5.21 (2H, s), 3.28 (3H, s). LCMS: tR = 1.82 min,
360, (M+H)+ calcd for C11H10Br2N2O2. HRMS: (M+H)+ calcd for
C11H10Br2N2O2: 360.9187, found: 360.9179.
4.1.2.3. {2-[4-(4,5-Dibromo-1-methoxymethyl-1H-imidazol-2-yl)-
phenoxy]-ethyl}-dimethyl-amine (5). 4-(4,5-Dibromo-1-meth-
oxymethyl-1H-imidazol-2-yl)-phenol 4 (300 mg, 0.83 mmol),
Cs2CO3 (649 mg, 1.99 mmol) and 2-dimethylaminoethyl chloride
hydrochloride (143 mg, 0.99 mmol) were dissolved in DMF
(4 mL). The solution was stirred at 40 C overnight, then diluted
with water (20 mL) and extracted with EtOAc (3  10 mL). The or-
ganic layer was washed with brine (10 mL), dried (MgSO4) and the
solvent removed under vacuum to yield 259 mg of 5 as a pale yel-
low oil. (Yield: 72%). 1H NMR (250 MHz, CDCl3) d ppm: 7.69 (2H, d,
J = 8.9 Hz), 7.00 (2H, d, J = 9.0 Hz), 5.25 (2H, s), 4.12 (2H, t,
J = 5.7 Hz), 3.46 (3H, s), 2.76 (2H, t, J = 5.7 Hz), 2.36 (6H, s). LCMS:
tR = 1.37 min, 432 (M+H)+ calcd for C15H19Br2N3O2.
4.1.2.4. {2-[4-(4-Bromo-1-methoxymethyl-5-pyridin-4-yl-1H-
imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amine (6). {2-[4-(4,5-
Dibromo-1-methoxymethyl-1H-imidazol-2-yl)-phenoxy]-ethyl}-
dimethyl-amine 5 (208 mg, 0.480 mmol), 4-pyridyl-boronic ester
(59 mg, 0.480 mmol), PPh3 (12.6 mg, 0.048 mmol), and K2CO3
(530 mg, 3.840 mmol) were suspended in a 2:1 mixture of DME/
H2O (9 mL). The suspension was stirred vigorously whilst de-gas-
sing with N2 for 20 min before adding Pd(OAc)2 (5.4 mg,
0.024 mmol). The mixture was then reﬂuxed for 2 h, cooled to
room temperature, acidiﬁed to pH 1 with 1 M HCl and washed with
EtOAc (3  5 mL). The aqueous layer was basiﬁed with 2 M NaOH
to pH 14 and extracted with EtOAc (3  5 mL). This organic layer
was dried (MgSO4) and the solvent removed under vacuum. The
residue was puriﬁed by chromatography using a stepped gradient
of 5–10% NEt3 in EtOAc, then 1:10:89 MeOH/NEt3/EtOAc to give
43 mg of 6 as a yellow oil. (Yield: 21%). 1H NMR (360 MHz, CDCl3)
d ppm: 8.70–8.80 (2H, m), 7.75 (2H, d, J = 8.9 Hz), 7.56–7.64 (2H,
m), 6.97–7.09 (2H, m), 4.96 (2H, s), 4.14 (2H, t, J = 5.7 Hz), 3.34
(3H, s), 2.78 (2H, t, J = 5.7 Hz), 2.37 (6H, s). LCMS: tR = 1.06 min,
431 (M+H)+ calcd for C20H23BrN4O2. HRMS: (M+H)+ calcd for
C20H23BrN4O2: 431.1082, found: 431.1081.
4.1.2.5. {2-[4-(4-Bromo-5-pyridin-4-yl-1H-imidazol-2-yl)-phen-
oxy]-ethyl}-dimethyl-amine (7). {2-[4-(4-Bromo-1-methoxy-
methyl-5-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-di-
methyl-amine 6 (70 mg, 0.16 mmol) was dissolved in 1 mL 5 M
HCl and the reaction heated at 60 C for 1 h. The solvents were re-
moved under vacuum to yield 70 mg of imidazole 7 as HCl salt.
(Yield: quantitative). 1H NMR (360 MHz, MeOH) d ppm 8.82 (2H,
d, J = 6.8 Hz,), 8.65 (2H, d, J = 6.8 Hz,), 8.06 (2H, d, J = 9.1 Hz), 7.23
(2H, d, J = 9.1 Hz,), 4.39–4.55 (2H, m), 3.57–3.75 (2H, m), 3.02
(7H, s). LCMS: tR = 0.94 min, 387 (M+H)+ calcd for C18H19BrN4O.
4.1.3. General method for the synthesis of {2-[4-(4-aryl-5-pyri-
din-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amines
Imidazole 6 or 7 (1 equiv), boronic ester (1.2–2 equiv), PPh3
(0.1 equiv), and K2CO3 (8–10 equiv) were suspended in a 2:1 mix-
ture of DME/H2O (3–9 mL). The suspension was stirred vigorously
D. Niculescu-Duvaz et al. / Bioorg. Med. Chem. 18 (2010) 6934–6952 6943whilst de-gassing with N2 for 20 min before adding Pd(OAc)2
(0.01 equiv). The mixture was then reﬂuxed for 2 h to overnight,
cooled to room temperature, acidiﬁed to pH1 with 1 M HCl and
washed with EtOAc (3  5 mL). The aqueous layer was basiﬁed
with 2 M NaOH to pH14 and extracted with EtOAc (3  5 mL). This
organic layer was dried (MgSO4) and the solvent removed under
vacuum. The residue was puriﬁed by preparative HPLC to yield
the desired product as TFA salt.
4.1.3.1. {2-[4-(5-{4-[1-(4-Methoxy-benzyl)-1H-pyrazol-3-yl]-phe-
nyl}-1-methoxymethyl-4-pyridin-4-yl-1H-imidazol-2-yl)-phen-
oxy]-ethyl}-dimethyl-amine (8a). Using the general coupling
procedure with 1-(4-methoxy-benzyl)-3-[4-(4,4,5,5-tetramethyl-
[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-pyrazole 29a (77 mg, 0.20
mmol) and MOM protected imidazole 6 (71 mg, 0.16 mmol) gave
the title compound which was puriﬁed by chromatography on sil-
ica gel. Yield = 47 mg (48%). 1H NMR (360 MHz, MeOH) d ppm: 8.63
(2H, d, J = 5.9 Hz), 7.79 (2H, d, J = 8.6 Hz), 7.73 (2H, d, J = 8.2 Hz),
7.61 (1H, d, J = 2.3 Hz), 7.54 (2H, d, J = 5.9 Hz), 7.46 (2H, d,
J = 8.6 Hz), 7.24 (2H, d, J = 8.6 Hz), 7.17 (2H, d, J = 8.6 Hz), 6.90
(2H, d, J = 8.6 Hz), 6.64 (1H, d, J = 2.3 Hz), 5.29 (2H, s), 5.03 (2H,
s), 4.22 (2H, t, J = 5.4 Hz), 3.78 (3H, s), 3.26 (3H, s), 2.86 (2H, t,
J = 5.2 Hz), 2.41 (6H, s). LCMS: tR = 1.40 min, 615 (M+H)+ calcd for
C37H38N6O3.
4.1.3.2. {2-[4-(5-{4-[1-(4-Methoxy-benzyl)-4-methyl-1H-pyrazol-
3-yl]-phenyl}-1-methoxy methyl-4-pyridin-4-yl-1H-imidazol-2-
yl)-phenoxy]-ethyl}-dimethyl-amine (8b). Standard coupling
procedure using 1-(4-methoxy-benzyl)-4-methyl-3-[4-(4,4,5,5-
tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-pyrazole 29b
(63 mg, 0.16 mol) and MOM protected imidazole 6 (57 mg,
0.13 mmol) gave the title compound which was puriﬁed by chro-
matography on silica gel. Yield = 60 mg (73%). 1H NMR (250 MHz,
CDCl3) d ppm; 8.66 (2H, d, J = 5.9 Hz), 7.79 (2H, d, J = 8.7 Hz), 7.61
(2H, d, J = 11.5 Hz), 7.55 (2H, d, J = 11.2 Hz), 7.47 (2H, d,
J = 6.1 Hz), 7.21 (2H, d, J = 8.5 Hz), 7.11 (1H, s), 7.05 (2H, d,
J = 8.7 Hz), 6.87 (2H, d, J = 8.7 Hz), 5.20 (2H, s), 4.95 (2H, s), 4.14
(2H, t, J = 5.7 Hz), 3.78 (3H, s), 3.28 (3H, s), 2.78 (2H, t, J = 5.6 Hz),
2.36 (6H, s), 2.17 (3H, s). LCMS: tR = 1.39 min, 629 (M+H)+ calcd
for C38H40N6O3.
4.1.3.3. 3-(4-{2-[4-(2-Dimethylamino-ethoxy)-phenyl]-3-meth-
oxymethyl-5-pyridin-4-yl-3H-imidazol-4-yl}-phenyl)-1-(4-met-
hoxy-benzyl)-1H-pyrazole-4-carbonitrile (8c). Standard
coupling procedure using 1-(4-methoxy-benzyl)-3-[4-(4,4,5,5-tet-
ramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-pyrazole-4-carbo-
nitrile 37 (65 mg, 0.16 mol) and MOM protected imidazole 6
(57 mg, 0.13 mmol) gave the title compound which was puriﬁed
by chromatography on silica gel. Yield = 61 mg (73%). 1H NMR
(250 MHz, CDCl3) d ppm: 8.62 (2H, d, J = 6.1 Hz), 7.82 (2H, d,
J = 8.5 Hz), 7.72 (2H, d, J = 8.8 Hz), 7.63 (1H, s), 7.54 (2H, d,
J = 8.5 Hz), 7.39 (2H, d, J = 6.1 Hz), 7.17 (2H, d, J = 8.8 Hz), 6.98
(2H, d, J = 8.8 Hz), 6.83 (2H, d, J = 8.8 Hz), 5.18 (2H, s), 4.94 (2H,
s), 4.07 (3H, t, J = 5.7 Hz), 3.73 (3H, s), 3.21 (3H, s), 2.70 (2H, t,
J = 5.6 Hz), 2.29 (6H, s). LCMS: tR = 1.50 min, 640 (M+H)+ calcd for
C38H37N7O3.
4.1.3.4. [2-(4-{4-[1-(4-Methoxy-benzyl)-4,5-dihydro-1H-benzo
[g]indazol-7-yl]-1-methoxy methyl-5-pyridin-4-yl-1H-imidazol-
2-yl}-phenoxy)-ethyl]-dimethyl-amine (8e). The standard
coupling procedure using 1-(4-methoxybenzyl)-7-(4,4,5,5-tetra-
methyl-1,3,2-dioxaborolan-2-yl)-4,5-dihydro-1H-benzo[g]indazole
40 (37 mg, 0.09 mmol) and imidazole 6 (31 mg, 0.07 mmol) re-
sulted in 8e (13 mg, 29%). 1H NMR (250 MHz, CDCl3) d ppm: 8.68
(2H, br s), 7.67–7.86 (3H, m), 7.36–7.58 (3H, m), 7.16–7.34 (5H,
m), 7.06 (2H, d, J = 10.1 Hz), 6.88 (1H, d, J = 8.7 Hz), 5.25 (2H, s),4.96 (2H, s), 4.15 (2H, t, J = 5.7 Hz), 3.78 (3H, s), 3.29 (3H, s),
2.65–2.90 (6H, m), 2.37 (6H, s). LCMS: tR = 1.41 min, 641 (M+H)+
calcd for C39H40N6O3.
4.1.3.5. [2-(4-{4-[1-(4-Methoxy-benzyl)-1H-benzo[g]indazol-7-
yl]-1-methoxymethyl-5-pyridin-4-yl-1H-imidazol-2-yl}-phen-
oxy)-ethyl]-dimethyl-amine (8f). The standard coupling proce-
dure using 1-(4-methoxy-benzyl)-7-(4,4,5,5-tetramethyl-[1,3,2]
dioxaborolan-2-yl)-1H-benzo[g]indazole 43 (53 mg, 0.13 mmol)
and imidazole 6 (71 mg, 0.16 mmol) resulted in 8f (33 mg, crude).
Taken into next step without further puriﬁcation. LCMS: tR = 1.47
min, 639 (M+H)+ calcd for C39H38N6O3.
4.1.3.6. 7-{2-[4-(2-Dimethylamino-ethoxy)-phenyl]-1-methoxy-
methyl-5-pyridin-4-yl-1H-imidazol-4-yl}-2,4,4a,5-tetrahydro-
indeno[1,2-c]pyridazin-3-one (8g). The standard coupling pro-
cedure using 7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,4,
4a,5-tetrahydro-indeno[1,2-c]pyridazin-3-one 26 (60 mg, 0.19
mmol) and imidazole 6 (99 mg, 0.23 mmol) resulted in 8g
(65 mg, 63%). 1H NMR (360 MHz, CDCl3) d ppm: 8.72 (2H, d,
J = 6.1 Hz), 8.48 (1H, s), 7.79 (2H, d, J = 8.9 Hz), 7.67 (1H, br s),
7.56 (1H, d, J = 7.9 Hz), 7.47 (2H, d, J = 6.1 Hz), 7.40 (1H, d,
J = 8.4 Hz), 7.06 (2H, d, J = 8.9 Hz), 4.95 (2H, s), 4.16 (2H, t,
J = 5.7 Hz), 3.10–3.43 (5H, m), 2.91 (1H, dd, J = 16.6, 7.3 Hz), 2.81
(2H, t, J = 5.7 Hz), 2.70 (1H, dd, J = 16.3, 5.9 Hz), 2.29–2.42 (7H,
m). LCMS: tR = 1.11 min, 537 (M+H)+ calcd for C31H32N6O3.
4.1.3.7. {2-[4-(5-{4-[4-Chloro-1-(4-methoxy-benzyl)-1H-pyra-
zol-3-yl]-phenyl}-4-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-
ethyl}-dimethyl-amine (9d). Standard coupling procedure using
4-chloro-1-(4-methoxy-benzyl)-3-[4-(4,4,5,5-tetramethyl-[1,3,2]-
dioxaborolan-2-yl)-phenyl]-1H-pyrazole 33 (30 mg, 0.071 mmol)
and deprotected imidazole hydrochloride 7 (27 mg, 0.059 mmol)
gave the title compound 9d which was puriﬁed by chromatogra-
phy on silica gel. Yield = 18 mg (51%). 1H NMR (360 MHz, MeOH)
d ppm: 8.41 (2H, d, J = 5.9 Hz), 7.90–7.96 (4H, m), 7.77 (1H, s),
7.51–7.58 (4H, m), 7.26 (2H, d, J = 9.1 Hz), 7.06 (2H, d, J = 9.1 Hz),
6.90 (2H, d, J = 8.6 Hz), 5.24 (2H, s), 4.16 (2H, t, J = 5.4 Hz), 3.76
(3H, s), 2.83 (2H, t, J = 5.4 Hz), 2.39 (6H, s). LCMS: tR = 1.41 min,
605 (M+H)+ calcd for C35H 32ClN5O2.
4.1.4. Synthesis and characterization of intermediates 11–16
(Scheme 2)
4.1.4.1. 1-Methoxyimino-indan-5-carbaldehyde (11). 5-Bromo-
2,3-dihydro-1H-inden-1-one O-methyl oxime 10 (3.71 g, 15.45
mmol) was dissolved in dry THF (75 mL). Solution was de-gassed
over N2 and then cooled to 78 C. nBuLi (1.6 M in THF, 10.63 mL,
17.0 mmol) was added dropwise. Stirring at 78 C was continued
for a further 10 min, before adding dry DMF (1.32 mL). Reaction
was allowed to graduallywarm to room temperature over 3 h. Reac-
tion was then quenched with saturated NaHCO3 and THF was evap-
orated under vacuum. Residue was dissolved in EtOAc and washed
with water, brine and dried (MgSO4), and solvent removed to leave
a brown oil. Puriﬁcationwas achieved by Flash Column Chromatog-
raphy on Silica gel, eluting in 5–10% EtOAc/heptane. Yield: 2.27 g
(78%). 1H NMR (250 MHz, CDCl3) d ppm: 9.95 (1H, s), 7.64–7.80
(3H, m), 3.95 (3H, s), 2.98–3.09 (2H, m), 2.81–2.93 (2H, m). LCMS:
tR = 1.84 min, 190 (M+H)+ calcd for C11H11NO2.
4.1.4.2. 5-(1-Hydroxy-2-pyridin-4-yl-2-TBDMS-hydroxy-propyl)-
indan-1-one O-methyl-oxime (12). 4-(tert-Butyl-dimethyl-sila-
nyloxymethyl)-pyridine (2.80 g, 12.5 mmol) was dissolved in dry
THF (20 mL) and the solution was de-gassed over N2. Reaction
was cooled to 40 C (MeCN:Cardice) and the LDA (2 M sol,
7.43 mL, 11.4 mmol) was added dropwise. Reaction was stirred at
40 C under N2 for 30 min, whereupon a de-gassed solution of
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THF (20 mL), was added dropwise and the reaction mixture gradu-
ally allowed to warm to room temperature over 3 h. Reaction mix-
ture was quenched with satd Na2HCO3 and the THF was removed
under vacuum. Residue was taken up in EtOAc, washed with satd
Na2HCO3, water, brine and dried (MgSO4). Solvent was removed
under vacuum to leave a yellow oil which was puriﬁed by Flash
Column Chromatography on silica gel, eluting the desired product
in 50–100% EtOAc/heptane. Yield: 4.52 g (96%) as a yellow oil. 1H
NMR (250 MHz, CDCl3) d ppm: 8.60–8.72 (2H, m), 7.71–7.82 (1H,
m), 7.10–7.36 (4H, m), 4.69–5.00 (2H, m), 4.13–4.20 (3H, m),
3.00–3.21 (4H, m), 0.96–1.10 (9H, m), 0.13 (6H, m). LCMS:
tR = 1.85 min 413 (M+H)+ calcd for C23H30N2O3Si.
4.1.4.3. 5-(1,2-Dihydroxy-2-pyridin-4-yl-ethyl)-indan-1-one
O-methyl-oxime (13). 5-(1-Hydroxy-2-pyridin-4-yl-2-TBDMS-
hydroxy-propyl)-indan-1-one O-methyl-oxime 12 (1.24 g, 3.01
mmol) was dissolved in dry THF (50 mL) and TBAF (1 M in THF)
(4.81 mL, 4.81 mmol) was added. Reaction mixture was stirred at
room temperature over night. Solvent was removed under vacuum
and residuewas puriﬁed by Flash ColumnChromatography on silica
gel, eluting the desired product in 5%MeOH/DCMas a colourless so-
lid. Yield: 797 mg (89%). 1H NMR (250 MHz, CDCl3) d ppm: 8.39 (1H,
dt, J = 4.30, 1.81 Hz), 7.54 (1H, d, J = 8.07 Hz), 6.94–7.13 (4H, m),
4.93–5.17 (1H, m), 4.62–4.78 (1H, m), 3.98 (3H, s), 2.77–3.02 (4H,
m). LCMS: tR = 1.06 min, 299 (M+H)+ calcd for C17H18N2O3.
4.1.4.4. 1-(1-Methoxyimino-indan-5-yl)-2-pyridin-4-yl-ethane-
1,2-dione (14). DMSO (705 ll, 9.95 mmol) was dissolved in dry
DCM (6.4 mL) and cooled to 78 C under N2. Oxalyl chloride
(653 lL, 7.50 mmol) was then added dropwise and the solution
was stirred for 20 min. A solution of diol 13 (671 mg, 2.25 mmol)
in dry DCM (6.4 mL) and DMSO (959 lL, 6.0 mmol) was added
dropwise at 78 C and the solution was stirred for 30 min. Trieth-
ylamine (1.94 mL, 14.0 mmol) was then added dropwise and the
reaction mixture was gradually allowed to warm to room temper-
ature over 3 h. Reaction mixture was diluted with water and ex-
tracted with DCM (3  20 mL), washed with brine, dried (MgSO4)
and evaporated to dryness under vacuum to leave a yellow solid.
Puriﬁed by Flash column chromatography on silica gel, eluting
the desired product in 50–100% EtOAc/heptane. Yield: 1.15 g
(quantitative) as a yellow solid. 1H NMR (250 MHz, CDCl3) d
ppm: 8.78–9.06 (2H, m), 7.71–7.97 (5H, m), 4.04 (3H, s), 3.04–
3.18 (2H, m), 2.81–3.02 (2H, m). LCMS: tR = 2.07 min, 295 (M+H)+
calcd for C17H14N2O3.
4.1.4.5. 5-{2-[2-(4-(4-methylpiperazin-1-yl)-5-(pyridine-4-yl)-
1H-imidazol-4-yl)]}-1H-inden-1-one-O-methyl-oxime (15a). 4-
(40-N-Methyl-pyrazinyl)-benzaldehyde (135 mg, 0.66 mmol) was
dissolved in acetic acid (3 mL), diketone 14 (150 mg, 0.51 mmol)
and ammonium acetate (393 mg, 5.10 mmol) was added. The reac-
tionmixture was heated to 100 C and stirred for 1 h. Reactionmix-
ture was basiﬁed with NH3, and diluted with water. Aqueous was
extracted with DCM (3  10 mL), dried (MgSO4) ﬁltered and evapo-
rated under vacuum. Puriﬁcation was carried out by Flash column
chromatography on silica gel, eluting the desired product in
5–10% MeOH/DCM, to yield imidazole 15a. Yield: 93.5 mg (38%).
1H NMR (250 MHz, MeOD) d ppm: 8.43 (2H, dd, J = 4.7, 1.5 Hz),
7.89 (2H, d, J = 9.0 Hz), 7.69 (1H, d, J = 8.1 Hz), 7.48–7.58 (3H, m),
7.38 (1H, s), 7.08 (2H, d, J = 9.0 Hz), 3.97 (3H, s), 3.25–3.35 (4H,
m), 3.02–3.08 (2H, m), 2.88–2.96 (2H, m), 2.68–2.78 (4H, m), 2.44
(3H, s). LCMS: tR = 1.21 min, 479 (M+H)+ calcd for C29H30N6O.
4.1.4.6. 5-{2-[4-(2-Dimethylamino-ethoxy)-phenyl]-5-pyridin-
4-yl-1H-imidazol-4-yl}-indan-1-one O-methyl-oxime (15b). 4-
(2-Dimethylamino-ethoxy)-benzaldehyde (367 mg, 1.90 mmol) was
reacted with diketone 14 (428 mg, 1.45 mmol) as described forcompound 15a to give O-methyl oxime 15b (197 mg, 29%) as a yel-
low oil. 1H NMR (250 MHz, MeOD) d ppm: 8.42 (2H, dd, J = 4.8,
1.29 Hz), 7.90–7.97 (2H, m), 7.68 (1H, d, J = 8.1 Hz), 7.45–7.57
(3H, m), 7.37 (1H, dd, J = 8.1, 1.2 Hz), 7.07 (2H, d, J = 9.0 Hz), 4.16
(2H, t, J = 5.4 Hz), 3.96 (3H, s), 2.99–3.10 (2H, m), 2.85–2.95 (2H,
m), 2.80 (2H, t, J = 5.5 Hz), 2.36 (s, 6H). LCMS: tR = 1.19 min, 468
(M+H)+ calcd for C28H29N5O2.4.1.4.7. (E)-tert-Butyl 4-(4-(1-(methoxyimino)-2,3-dihydro-1H-
inden-5-yl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)piperidine-1-car-
boxylate (15c). 4-Formyl-piperidine-1-carboxylic acid tert-butyl
ester (141 mg 0.66 mmol) was reacted with diketone 14 (150 mg,
0.51 mmol) as described for 15a to give O-methyl oxime 15c
(229 mg, 92%). 1H NMR (250 MHz, MeOD) d ppm: 8.41 (2H, d,
J = 5.94 Hz), 7.67 (1H, d, J = 8.22 Hz), 7.45 (3H, d, J = 12.03 Hz),
7.32 (1H, d, J = 8.22 Hz), 4.22 (2H, d, J = 12.94 Hz), 3.96 (3H, s),
2.83–3.11 (7H, m), 1.94–2.07 (2H, m), 1.71–1.92 (2H, m), 1.48 (s,
9H). LCMS: tR = 1.55 min, 488 (M+H)+ calcd for C28H33N5O3.4.1.4.8. 5-(2-(4-(4-Methylpiperazin-1-yl)phenyl)-5-(pyridin-4-
yl)-1H-imidazol-4-yl)-2,3-dihydro-1H-inden-1-one (16a). 5-{2-
[2-(4-(4-Methylpiperazin-1-yl)-5-(pyridine-4-yl)-1H-imidazol-4-
yl)]}-1H-inden-1-one-O-methyl-oxime 15a (93.5 mg, 0.20 mmol)
was dissolved in dioxane (4 mL) and 5 M HCl (2 mL) was added.
The reaction was heated to 80 C overnight. Solvents were evapo-
rated under vacuum and residue was puriﬁed by Flash column
chromatography on silica gel, eluting the desired product in
5–50% MeOH/DCM to give ketone 16a. Yield: 87 mg (99%). 1H
NMR (250 MHz, MeOD) d ppm: 8.83 (2H, br s), 8.05–8.27 (4H,
m), 7.49–7.96 (3H, m), 7.30 (2H, d, J = 7.3 Hz), 4.17 (2H, br s),
3.55–3.78 (5H, m), 3.34–3.46 (3H, m), 2.91–3.06 (4H, m),
2.68–2.84 (1H, m). LCMS: tR = 1.08 min, 450 (M+H)+ calcd for
C28H28N6O.
4.1.4.9. {2-[4-(5-Indanyl-1-one)-5-pyridin-4-yl-1H-imidazol-2-
yl]-phenoxy]-ethyl}-dimethyl-amine (16b). 5-{2-[4-(2-Dimeth-
ylamino-ethoxy)-phenyl]-5-pyridin-4-yl-1H-imidazol-4-yl}-indan-
1-one O-methyl-oxime 15b (164 mg, 0.35 mmol) was treated as
described for compound 16a to give ketone 16b (36 mg, 23%) as
a yellow oil. 1H NMR (250 MHz, MeOD) d ppm: 8.47 (2H, d,
J = 6.1 Hz), 7.97 (2H, d, J = 8.8 Hz), 7.72 (2H, s), 7.55 (3H, br s),
7.10 (2H, d, J = 8.8 Hz), 4.19 (2H, t, J = 5.4 Hz), 3.15–3.40 (2H, m),
2.62–2.91 (4H, m), 2.38 (6H, s). LCMS: tR = 1.08 min, 439 (M+H)+
calcd for C27H26N4O2.4.1.4.10. tert-Butyl 4-(4-(1-oxo-2,3-dihydro-1H-inden-5-yl)-5-
(pyridin-4-yl)-1H-imidazol-2-yl)piperidine-1-carboxylate (16c).
tert-Butyl 4-(4-(1-(methoxyimino)-2,3-dihydro-1H-inden-5-yl)-5-
(pyridin-4-yl)-1H-imidazol-2-yl)piperidine-1-carboxylate 15c
(229 mg, 0.47 mmol) was dissolved in 5 M HCl (2 mL) and dioxane
(4 mL) and heated at 80 C overnight. All solvents were removed
under vacuum to leave a brown oil (LCMS: tR = 0.86 min, 359
(M+H)+ calcd for C22H22N4O). This was dissolved in THF (15 mL)
and water (2 mL) before adding DIPEA (90 lL, 0.52 mmol) and
(BOC)2O (256 mg, 1.17 mmol). After stirring at room temperature
overnight, the THF was evaporated, further water added and ex-
tracted with DCM (3). The combined organic phases were dried
(MgSO4), ﬁltered and evaporated to leave an oil which was puriﬁed
by Flash column chromatography on silica gel, eluting the desired
compound with 0–10% MeOH/DCM. Yield = 122 mg (57%). 1H NMR
(250 MHz, MeOD) d ppm: 8.45 (2H, br s), 7.57–7.79 (2H, m), 7.34–
7.54 (3H, m), 4.22 (2H, d, J = 12.6 Hz), 3.15–3.40 (2H, m), 2.86–3.08
(3H, m), 2.72 (2H, t), 1.95–2.09 (2H, m), 1.84 (2H, t, J = 12.0 Hz),
1.48 (9H, s). LCMS: tR = 1.44 min, 459 (M+H)+ calcd for C27H30N4O3.
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(Scheme 4)
4.1.5.1. Methyl, 2,3-dibromofuranyl-carboxylate (17). To a solu-
tion of the 2,3-dibromofuran-5-yl carboxylic acid (4 g, 14.8 mmol)
in DCM (60 mL) was added oxalyl chloride (3.88 mL, 44.5 mmol)
under nitrogen. The reaction mixture was cooled to 0 C and
0.2 mL of DMF added. The reaction was stirred at room tempera-
ture for 4 h, solvent was removed under vacuum and azeotroped
with DCM. The crude was dissolved in DCM (40 mL) and MeOH
added at 0 C. The reaction was stirred at room temperature for
1 h and solvent removed under vacuum. Yielded product was ob-
tained as a pure solid (3.85 g) in 91% yield. 1H NMR (250 MHz,
CDCl3-d) d ppm: 7.11 (1H, s), 3.83 (3H, s).
4.1.5.2. Methyl, 2-(4-pyridyl),3-bromofuranyl-carboxylate (18).
Dry DMF (150 mL) was added to a dry mixture of the dibromofuran
17 (5.68 g, 20.0 mmol), 4-pyridyl boronic acid (2.7 g, 22.0 mmol),
Cs2CO3 (19 g, 60 mmol), AsPh3 (0.610 g, 2 mmol), and (PPh3)2PdCl2
(1.12 g, 1.6 mmol). This solution was de-gassed with nitrogen for
20 min before being heated to 90 C overnight. The majority of
DMF was then removed under vacuum and the crude diluted with
EtOAc. The crude organic was washed with NaHCO3 (1% aqueous)
and dried (MgSO4). Puriﬁcation followed using ﬂash column chro-
matography on silica gel eluting with EtOAc/heptane to yield
2.12 g of product (37%) as an off-white solid. 1H NMR (250 MHz,
CDCl3-d) d ppm: 8.73 (2H, d, J = 6.2 Hz), 7.93–7.99 (2H, m), 7.30
(1H, s), 3.95 (3H, s). LCMS: tR = 1.35 min, 282 (M+H)+ calcd for
C11H8BrNO3.
4.1.5.3. Methyl 4-(1-(methoxyimino)-2,3-dihydro-1H-inden-5-
yl)-5-(pyridin-4-yl)furan-2-carboxylate (19). Dry DMF (150 mL)
was added to a dry mixture of 18 (0.590 g, 2.1 mmol), 1-(methoxy-
imino)-2,3-dihydro-1H-inden-5-ylboronic acid (0.512 g, 2.5 mmol),
Cs2CO3 (2.05 g, 6.3 mmol), AsPh3 (0.640 g, 2.1 mmol), and (PPh3)2
PdCl2 (1.05 g, 1.5 mmol). This solution was de-gassed with nitrogen
for 20 min before being heated to 90 C overnight. The majority of
DMF was then removed under vacuum and the crude diluted with
EtOAc. The crude organic was washed with 1% aqueous NaHCO3
and dried (MgSO4). Puriﬁcation followed using ﬂash column chro-
matography on silica gel eluting with EtOAc/heptane to yield
0.519 g of product (69%) as an off-white solid. 1H NMR (250 MHz,
CDCl3-d) d ppm: 8.48 (2H, d, J = 4.8 Hz), 7.66 (1H, d, J = 8.1 Hz),
7.37–7.42 (2H, m), 7.15–7.23 (3H, m), 3.93 (3H, s), 3.87 (3H, s),
2.94–3.02 (2H, m), 2.81–2.90 (2H, m). LCMS: tR = 1.84 min, 363
(M+H)+ calcd for C21H18N2O4.
4.1.5.4. 2-(4-Pyridyl)-3-(5-indanyl-N-O-methyl-oxime)-furanyl-
5-carboxylic acid (20). To a solution of 19 (335 mg, 0.93 mmol)
in 5 mL THF/MeOH (4:1) was added 2 M aqueous NaOH (0.95 mL,
1.90 mmol). The reaction was stirred vigorously at room tempera-
ture for 90 min and solvent was removed under vacuum to yield
220 mg product (68%) as a white solid. 1H NMR (250 MHz,
DMSO-d6) d ppm: 8.26 (2H, d, J = 6.8 Hz), 7.97 (2H, d, J = 6.5 Hz),
7.65 (1H, d, J = 8.1 Hz), 7.53 (2H, s), 7.38 (1H, d, J = 7.8 Hz), 3.88
(3H, s), 2.96–3.08 (2H, m), 2.76–2.88 (2H, m). LCMS: tR = 1.40 min,
349 (M+H)+ calcd for C20H16N2O4.4.1.5.5.4-(1-Oxo-2,3-dihydro-1H-inden-5-yl)-5-(pyridin-4-yl)fu-
ran-2-carboxylic acid (21). To a solution of starting acid 20
(835 mg, 2.41 mmol) dioxane/acetone (8 mL:1.5 mL) was added
5 mL aqueous hydrochloric acid. The reaction was heated at 90 C
for 90 min. Solvent was removed under vacuum to give 1.41 g of
pure product (quantitative, some NaCl present). 1H NMR
(250 MHz, MeOD) d ppm: 9.48 (2H, d, J = 7.8 Hz), 8.70 (2H, d,
J = 7.7 Hz), 8.45–8.54 (2H, m), 8.24–8.33 (2H, m), 3.90–3.95 (2H,m), 3.42–3.50 (2H, m). HRMS: (M+H)+ calcd for C19H13NO4:
320.0923, found: 320.0915.
4.1.5.6. 2-(4-Pyridyl)-3-(5-indanyl-oxime)-furanyl-5-carbonyl-
4-N-methyl-piperidine (22a). To a solution of acid 21 (300 mg,
0.95 mmol) in DMF was added DIC (13 mg, 1.05 mmol), methyl
piperazine (105 mg, 1.05 mmol), HOBt (141 mg, 1.05 mmol), and
TEA (146 lL, 1.05 mmol). The reaction was heated to 60 C for
4 h. Solvent was removed under vacuum and the residue was puri-
ﬁed by chromatography on silica gel eluting with DCM/MeOH. This
yielded 150 mg (40%) of pure product as a white powder. LCMS:
tR = 0.97 min, 402 (M+H)+ calcd for C24H23N3O3.
4.1.5.7. 5-{5-[4-(2-Dimethylamino-ethyl)-piperidine-1-carbon-
yl]-2-pyridin-4-yl-furan-3-yl}-indan-1-one (22b). Acid 21 (250
mg, 0.78 mmol) was coupled with dimethyl-(2-piperazin-1-yl-
ethyl)-amine (135 mg, 0.86 mmol) as described for 22a to give
22b. Yield = 176 mg (49%). 1H NMR (360 MHz, CDCl3) d ppm:
8.58 (2H, d, J = 6.4 Hz), 7.81 (1H, d, J = 7.9 Hz), 7.52 (1H, s), 7.41
(1H, d, J = 7.9 Hz), 7.37 (2H, d, J = 6.1 Hz), 7.14 (1H, s), 3.91 (4H,
br s), 3.12–3.25 (2H, m), 2.69–2.85 (2H, m), 2.40–2.69 (8H, m),
2.28 (6H, s). LCMS: tR = 1.05 min, 459 (M+H)+ calcd for C27H30N4O3.
4.1.5.8. 5-{5-[4-Morpholine-1-carbonyl]-2-pyridin-4-yl-furan-
3-yl}-indan-1-one (22c). Acid 21 (766 mg; 2.4 mmol) was cou-
pled with morpholine (0.23 mL; 2.6 mmol) as described for 22a
to give 22c. Yield = 520 mg (56%). 1H NMR (250 MHz, CDCl3) d
ppm: 8.58 (2H, dd, J = 4.6, 1.6 Hz), 7.81 (1H, d, J = 7.9 Hz), 7.52
(1H, s), 7.33–7.44 (3H, m), 7.18 (1H, s), 3.75–4.07 (8H, m), 3.13–
3.23 (2H, m), 2.72–2.81 (2H, m). LCMS: tR = 1.29 min, 389 (M+H)+
calcd for C23H20N2O4.
4.1.5.9. tert-butyl 4-(4-(1-oxo-2,3-dihydro-1H-inden-5-yl)-5-
(pyridin-4-yl)furan-2-carbonyl)piperazine-1-carboxylate (22d).
Acid 21 (385 mg; 1.21 mmol) was coupled with N-Boc piperazine
(248 mg; 1.33 mmol) as described for 22a to give 22d and was
used in the next step without further puriﬁcation. LCMS: tR =
1.71 min, 488 (M+H)+ calcd for C28H29N3O5.
4.1.6. Synthesis and characterization of intermediates 24–33
(Scheme 5)
4.1.6.1. (5-Bromo-1-oxo-indan-2-yl)-acetic acid ethyl ester (24). LDA
(2 M in hexane, 5.21 mL, 10.42 mmol) was mixed with THF (5 mL)
and cooled to 78 C. 5-Bromo-indan-1-one (2.0 g, 9.48 mmol) in
THF (20 mL) was added dropwise under a stream of nitrogen and
the solution was stirred for 30 min. Bromo-acetic acid ethyl ester
(1.74 g, 10.42 mmol) in HMPA (1.5 mL) and THF (5 mL) was added
dropwise to the reaction mixture, which was then allowed to
warm up to room temperature overnight. The reaction was
quenched with NH4Cl saturated solution (50 mL) and extracted
with EtOAc (3  50 mL), the organic layer was dried (MgSO4), ﬁl-
tered and the solvent removed under vacuum. The residue was
puriﬁed by chromatography using a stepped gradient of 0–8%
EtOAc in heptane to yield 24 as a white solid. Yield: 577 mg, 20%.
1H NMR (360 MHz, CDCl3) d ppm: 7.59–7.68 (2H, m), 7.53 (1H, d,
J = 9.1 Hz), 4.14 (2H, q, J = 7.0 Hz), 3.44 (1H, dd, J = 17.1, 7.8 Hz),
2.83–3.06 (3H, m), 2.62–2.73 (1H, m), 1.23 (3H, t, J = 7.0 Hz). LCMS:
tR = 2.07 min, 297 (M+H)+ calcd for C13H13BrO3. HRMS: (M+H)+
calcd for C13H13BrO3: 297.0126, found: 297.0119.
4.1.6.2. 7-Bromo-2,4,4a,5-tetrahydro-indeno[1,2-c]pyridazin-3-
one (25). Intermediate 24 (250 mg, 0.84 mmol) was dissolved in
EtOH (3 mL) and NH2NH2H2O (0.15 mL, 4.21 mmol) was added
in EtOH (1 mL) and stirred at room temperature overnight. A pre-
cipitate appeared which was ﬁltered and washed with EtOH
(10 mL) to yield compound 25 as a white solid. Yield: 134 mg,
Scheme 5. Synthesis of boronic acids 26, 29a, 29b and 33. Reagents and conditions: (i) 2M LDA, THF, BrCH2CO2Et; (ii) H2NNH2, EtOH; (iii) bis pinacolato-diboron, KOAc,
Pd(dppf)Cl2, DMF, 90 C; (iv) 4-methoxy benzyl chloride, NaH, DMF; (v) NCS, DCM; (vi) (BOC)2O, DMAP, CH3CN.
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(2H, m), 7.47–7.51 (1H, m), 3.37–3.47 (1H, m), 3.15–3.27 (1H,
m), 2.93 (1H, dd, J = 16.6, 7.5 Hz), 2.75 (1H, dd, J = 16.6, 6.1 Hz),
2.37 (1H, t, J = 16.3 Hz). LCMS: tR = 1.65 min, 265 (M+H)+ calcd
for C11H8BrN2O3.
4.1.6.3. 7-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,4,4a,
5-tetrahydro-indeno[1,2-c]pyridazin-3-one (26). Bromo inter-
mediate 25 (145 mg, 0.55 mmol), potassium acetate (160 mg,
1.64 mmol), bis(pinacolato)diboron (208 mg, 0.82 mmol) and 1,1-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride (20 mg,
0.05 mmol) were dissolved in dry DMF (3 mL). The reaction was
heated to 80 C in a sealed tube for 2 h, quenched with H2O
(15 mL), extracted into EtOAc (3  10 mL) and dried (Na2SO4). Or-
ganic solvent was removed in vacuo. The residue was puriﬁed by
chromatography using a stepped gradient of 10–50% EtOAc in hep-
tane to yield 26 as a white solid (88 mg, 51%). 1H NMR (360 MHz,
CDCl3) d ppm: 8.47 (1H, s), 7.83 (1H, s), 7.66–7.82 (2H, m), 3.44
(1H, dd, J = 16.3, 8.6 Hz), 3.11–3.26 (1H, m), 2.93 (1H, dd, J = 16.3,
7.3 Hz), 2.75 (1H, dd, J = 16.3, 5.9 Hz), 2.37 (1H, t, J = 16.3 Hz),1.37 (12H, s). LCMS: tR = 1.89 min, 313 (M+H)+ calcd for C17H22
BN2O3. HRMS: (M)+ calcd for C17H21BN2O3: 312.1760, found:
312.1747.
4.1.6.4. 3-(4-Bromo-phenyl)-1-(4-methoxy-benzyl)-1H-pyrazole
(28a). 3-(4-Bromophenyl)pyrazole 27a (223 mg, 1 mmol) was
dissolved in anhydrous DMF (2.2 mL) and added to 60% NaH in
mineral oil (44 mg, 1.1 mmol) previously washed with diethyl
ether. After stirring for 20 min at room temperature, 4-methoxy-
benzyl chloride (0.15 mL; 1.1 mmol) was added and stirring con-
tinued at room temperature for a further 4 h. Water (5 mL) was
then added and the emulsion extracted with EtOAc (2  3 mL).
The combined organic phases were washed with saturated sodium
bicarbonate (3  2 mL) and dried (MgSO4). After ﬁltration and
evaporation, the oil crystallised to give the product (352 mg,
100%). 1H NMR (250 MHz, CDCl3) d ppm: 7.66–7.73 (2H, m), 7.51
(2H, d, J = 8.7 Hz), 7.33 (1H, d, J = 2.3 Hz), 7.23 (2H, d, J = 8.8 Hz),
6.89 (2H, d, J = 8.7 Hz), 6.53 (1H, d, J = 2.3 Hz), 5.29 (2H, s), 3.81
(3H, s). The product was used in the next step without further
puriﬁcation.
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1H-pyrazole (28b). 4-Methyl-3-(4-bromophenyl)pyrazole 27b
(474 mg, 2.0 mmol) was dissolved in anhydrous DMF (5 mL) and
added to 60% NaH in mineral oil (88 mg, 2.2 mmol) previously
washed with heptane. After stirring for 20 min at room tempera-
ture, 4-methoxybenzyl chloride (0.3 mL, 2.2 mmol) was added
and stirring continued at room temperature for a further 3.5 h.
Water (10 mL) was then added and the emulsion extracted with
EtOAc (2  10 mL). The combined organic phases were washed
with saturated sodium bicarbonate (3  20 mL) and dried (MgSO4).
After ﬁltration and evaporation, the oil crystallised to give the
product (697 mg, 98%). 1H NMR (360 MHz, CDCl3) d ppm: 7.58–
7.63 (2H, m), 7.56 (2H, d), 7.26 (2H, d, J = 8.6 Hz), 7.17 (1H, br s),
6.92 (2H, d, J = 8.6 Hz), 5.25 (2H, s), 3.84 (3H, s), 2.21 (3H, s). LCMS:
tR = 2.48 min, 357 (M+H)+ calcd for C18H17BrN2O. HRMS: (M+H)+
calcd for C18H17BrN2O: 357.0602, found: 357.0613.
4.1.6.6. 1-(4-Methoxy-benzyl)-3-[4-(4,4,5,5-tetramethyl-[1,3,2]
dioxaborolan-2-yl)-phenyl]-1H-pyrazole (29a). Using the same
boronylation procedure as described for 26, from 3-(4-bromo-phe-
nyl)-1-(4-methoxy-benzyl)-1H-pyrazole 28a (350 mg, 1.0 mmol)
the title compound was obtained (349 mg: 88%). 1H NMR
(360 MHz, CDCl3) d ppm: 7.83 (4H, s), 7.32 (1H, d, J = 2.7 Hz),
7.24 (2H, d, J = 8.6 Hz), 6.89 (2H, d, J = 8.6 Hz), 6.60 (1H, d,
J = 2.7 Hz), 5.31 (2H, s), 3.81 (3H, s), 1.37 (12H, s). LCMS:
tR = 2.49 min, 391 (M+H)+ calcd for C23H28BN2O3. HRMS: (M)+ calcd
for C23H27BN2O3: 390.2229, found: 390.2234.
4.1.6.7. 1-(4-Methoxy-benzyl)-4-methyl-3-[4-(4,4,5,5-tetramet-
hyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-pyrazole (29b). Stan-
dard boronylation procedure using 3-(4-bromo-phenyl)-1-(4-
methoxy-benzyl)-4-methyl-1H-pyrazole 28b (357 mg, 1.0 mmol)
gave the desired compound (284 mg, 70%). 1H NMR (250 MHz,
CDCl3) d ppm: 7.86 (2H, d, J = 7.5 Hz), 7.72 (2H, d, J = 7.9 Hz), 7.24
(2H, d, J = 8.7 Hz), 7.14 (1H, s), 6.89 (2H, d, J = 8.7 Hz), 5.24 (2H,
s), 3.81 (3H, s), 2.21 (3H, s), 1.37 (12H, s). HRMS: (M+H)+ calcd
for C24H29BN2O3: 404.2386, found: 404.2390.
4.1.6.8. 3-(4-Bromo-phenyl)-4-chloro-1H-pyrazole (30). 3-(4-
Br- omophenyl)-pyrazole 27a (223 mg, 1.0 mmol) and N-chloro-
succinimide (140 mg, 1.05 mmol) were dissolved in DCM (30 mL)
and stirred at room temperature for 84 h. The solvent was evapo-
rated and puriﬁed on a silica gel column with 10–25% EtOAc in
heptane to yield the desired product 30, 190 mg (74%). 1H NMR
(360 MHz, CDCl3) d ppm: 7.69 (2H, d, J = 5.8 Hz), 7.62 (1H, s),
7.58 (2H, d, J = 5.4 Hz). LCMS: tR = 2.04 min, 257 (M+H)+ calcd for
C9H6BrClN2.
4.1.6.9. 3-(4-Bromo-phenyl)-4-chloro-pyrazole-1-carboxylic acid
tert-butyl ester (31). 4-Chloro-3-(40-bromophenyl)-pyrazole 30
(190 mg, 0.74 mmol) was dissolved in acetonitrile (2.3 mL) with
heating. After cooling on ice, BOC anhydride (193 mg, 0.89 mmol)
and DMAP (9 mg; 0.1 mmol) were added and stirring continued
at 0 C for 2 h and room temperature for 1 h. The reaction was di-
luted with EtOAc (2 mL) and washed with 1.2 N HCl (2  2 mL),
saturated sodium bicarbonate (2 mL) and brine (2 mL) before dry-
ing (Na2SO4), ﬁltering and evaporating to leave the product as an
oil. Yield = 244 mg (92%). 1H NMR (250 MHz, CDCl3) d ppm: 8.11
(1H, s), 7.87 (2H, d, J = 8.7 Hz), 7.58 (2H, d, J = 8.8 Hz), 1.66 (9H,
s). LCMS: tR = 2.05 min, 298/300/302 (M+H-56 Boc fragmentation)+
calcd for C14H14BrClN2O2.
4.1.6.10. 4-Chloro-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaboro-
lan-2-yl)-phenyl]-1H-pyrazole (32). Using the sameboronylation
procedureas described for compound26,with3-(4-bromo-phenyl)-
4-chloro-pyrazole-1-carboxylic acid tert-butyl ester 31 (244 mg,0.68 mmol) caused the loss of the BOC group. A 1:1 mix of
unprotected 4-chloro-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxa boro-
lan-2-yl)-phenyl]-1H-pyrazole 32 and unprotected 4-chloro-3-(40-
bromophenyl)-pyrazole 30 was isolated after chromatography on
silica gel (116 mg, 61%). 1H NMR (360 MHz, CDCl3) d ppm: 7.91
(2H, d, J = 8.7 Hz), 7.79 (2H, d, J = 8.2 Hz), 7.60 (1H, s), 1.38 (12H, s).
LCMS: tR = 2.05 min, 257/259/261 (M+H)+ calcd for C9H6BrClN2
and 2.23 min, 305/307 (M+H)+ calcd for C15H18BClN2O2.
4.1.6.11. 4-Chloro-1-(4-methoxy-benzyl)-3-[4-(4,4,5,5-tetramet
hyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-pyrazole (33). The
(1:1) mixture of 30 and 32 resulted from the previous reaction
(116 mg, 0.41 mmol) was dissolved in anhydrous DMF (1 mL)
and added to 60% NaH in mineral oil (18 mg, 0.45 mmol) previ-
ously washed with heptane. After stirring for 10 min at room tem-
perature, 4-methoxybenzyl chloride (0.06 mL, 0.45 mmol) was
added and stirring continued at room temperature overnight.
Water (2.5 mL) was then added and the oil extracted with EtOAc
(2  2 mL). The combined organic phases were washed with satu-
rated NaHCO3 (2  2 mL), dried (MgSO4), ﬁltered and evaporated
to leave a 2:1 mix of boronyl and bromophenyl PMB protected pyr-
azoles (112 mg, 50% Br; 75%). 1H NMR (360 MHz, CDCl3) d ppm:
7.82 (2H, d, J = 8.6 Hz), 7.56 (2H, d, J = 8.6 Hz), 7.34 (1H, s), 7.25
(2H, dd, J = 8.6, 2.3 Hz), 6.91 (2H, d, J = 8.6 Hz), 5.22 (2H, s), 3.82
(3H, s), 1.37 (12H, s).
The crude mixture was subjected to standard boronylation pro-
cedure (as described for compound 26) affording the desired com-
pound (45 mg, 38%) after chromatography and crystallisation from
heptane. 1H NMR (360 MHz, CDCl3) d ppm: 7.85 (2H, d, J = 8.3 Hz),
7.79 (2H, d, J = 8.3 Hz), 7.26 (1H, s), 7.16 (2H, d, J = 8.5 Hz), 6.83
(2H, d, J = 8.6 Hz), 5.16 (2H, s), 3.74 (3H, s), 1.29 (12H, s). LCMS:
tR = 2.73 min, 425, 4 (M+H)+ calcd for C23H29BClN2O3.
4.1.7. Synthesis and characterization of intermediates 34–43
(Scheme 6)
4.1.7.1. 2-(4-Bromo-benzoyl)-3-dimethylamino-acrylonitrile (34).
4-Bromophenyl-2 oxopropionitrile (448 mg, 2.0 mmol) was dis-
solved in DMF (2 mL) and tris(dimethylamino)methane (1.04 mL,
6.0 mmol) was added. The reaction was heated at 70 C for 4 h before
cooling on ice and adding water (7 mL). The desired product was ﬁl-
tered off, washed with water and dried. Yield = 339 mg (61%). 1H
NMR (250MHz, CDCl3) d ppm: 7.97 (1H, s), 7.68 (2H, d, J = 10.2 Hz),
7.57 (2H, d, J = 9.9 Hz), 3.50 (3H, s), 3.32 (3H, s). The productwas used
in the next step without further puriﬁcation.
4.1.7.2. 3-(4-Bromo-phenyl)-1H-pyrazole-4-carbonitrile (35). 2-
(4-Bromo-benzoyl)-3-dimethylamino-acrylonitrile 34 (339 mg, 1.22
mmol) was suspended in ethanol (3.4 mL) and hydrazine hydrate
(77 mL, 1.58 mmol) was added. The starting material dissolved and
the reaction was stirred at room temperature for 3 h. The solvent
was evaporated and water (5 mL) added. The solid was ﬁltered off
and chromatographed on silica gel with 60:40 EtOAc/heptane to give
the desired product (233 mg; 77%). 1HNMR (250 MHz, acetone-d6): d
ppm: 8.44 (1H, s), 7.92 (2H, d, J = 8.5 Hz), 7.68–7.74 (3H, m). LCMS:
tR = 1.85 min, 248 (M+H)+ calcd for C10H6BrN3.
4.1.7.3. 3-(4-Bromo-phenyl)-1-(4-methoxy-benzyl)-1H-pyrazole-
4-carbonitrile (36). 3-(4-Bromo-phenyl)-1H-pyrazole-4-carboni-
trile 35 (233 mg, 0.94 mmol) was dissolved in anhydrous DMF
(2.3 mL)andadded to60%NaH inmineral oil (41 mg,1.03 mmol) pre-
viously washed with heptane. After stirring for 10 min at room tem-
perature, 4-methoxybenzyl chloride (0.14 mL; 1.03 mmol) was
added and stirring continued at room temperature for a further 4 h.
Water (5 mL)was then added and an oil separatedwhich crystallised
with stirring. This was ﬁltered and washed with water to leave the
product (309 mg, 89%). 1H NMR (360MHz, CDCl3) d ppm: 7.87 (2H,
Scheme 6. Synthesis of boronic acids 37, 40 and 43. Reagents and conditions: (i) HC(NMe2)3, DMF; (ii) H2NNN2H2O, EtOH; (iii) 4-methoxy benzyl chloride, NaH, DMF; (iv) bis
pinacolato-diboron, KOAc, Pd(dppf)Cl2, DMF, 90 C; (v) AcOH, H2NNH2; (vi) DDQ, dioxane.
6948 D. Niculescu-Duvaz et al. / Bioorg. Med. Chem. 18 (2010) 6934–6952d, J = 8.6 Hz), 7.72 (1H, s), 7.59 (2H, d, J = 8.6 Hz), 7.27 (2H, t,
J = 4.3 Hz), 6.94 (2H, d, J = 8.6 Hz), 5.28 (2H, s), 3.83 (3H, s). The prod-
uct was used in the next step without further puriﬁcation.
4.1.7.4. 1-(4-Methoxy-benzyl)-3-[4-(4,4,5,5-tetramethyl-[1,3,2]
dioxaborolan-2-yl)-phenyl]-1H-pyrazole-4-carbonitrile (37).
Standard boronylation procedure (as described for compound 26)
using 3-(4-bromo-phenyl)-1-(4-methoxy-benzyl)-1H-pyrazole-4-
carbonitrile 36 (309 mg, 0.84 mmol) gave the desired compound
(237 mg, 68%). 1H NMR (250 MHz, CDCl3) d ppm: 7.99 (2H, d,
J = 8.8 Hz), 7.90 (2H, d, J = 8.8 Hz), 7.72 (1H, s), 7.28 (2H, d,
J = 8.7 Hz), 6.94 (2H, d, J = 8.7 Hz), 5.29 (2H, s), 3.83 (3H, s), 1.37
(12H, s). LCMS: tR = 2.54 min, 416 (M+H)+ calcd for C24H27BN3O3.
HRMS: (M)+ calcd for C24H26BN3O3: 415.2182, found: 415.2175.
4.1.7.5. 7-Bromo-4,5-dihydro-1H-benzo[g]indazole (38). 6-Bro-
mo-3,4-dihydro-2H-naphthalen-1-one (204 mg, 0.91 mmol) was
dissolved in DMF (2mL) and tris-dimethylamino methane (657 mg,4.53 mmol) was added. The reaction was stirred for 1 h, then fur-
ther tris-dimethylamino methane (657 mg, 4.53 mmol) was added,
and the reaction stirred overnight. The solvents were removed un-
der vacuum and the residue azeothroped with heptane. The crude
was then dissolved in AcOH (2 mL) and treated with NH2NH2H2O
(227 mg, 4.53 mmol). The reaction was stirred for 15 min, upon
which concd NH4OH solution was added to pH 11. NaHCO3 satu-
rated solution (10 mL) was added and the aqueous layer was ex-
tracted with DCM (3  10 mL), dried (MgSO4) and the solvent
removed in vacuo to yield 38 as a red brick solid. Yield: 224 mg,
99%. 1H NMR (360 MHz, CDCl3) d ppm: 7.89 (1H, d, J = 8.2 Hz),
7.73 (1H, s), 7.43 (1H, dd, J = 8.4, 2.0 Hz), 7.34 (1H, d, J = 1.8 Hz),
2.88–2.97(2H, m), 2.79–2.85 (2H, m). LCMS: tR = 1.91 min, 249
(M+H)+ calcd for C11H9BrN2.
4.1.7.6. 7-Bromo-1-(4-methoxy-benzyl)-4,5-dihydro-1H-benzo-
[g]indazole (39). NaH (60% in mineral oil, 15.6 mg, 0.39 mmol)
was suspended in DMF (3.5 mL) and 7-bromo-4,5-dihydro-1H-
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The suspension was stirred for 10 min and PMBCl (61 mg,
0.39 mmol) was added dropwise. The reaction was stirred at room
temperature for 1 h. Water (10 mL) was added and the aqueous
layer was extracted with EtOAc (3  10 mL). The organic layer
was washed with water (2  10 mL) and brine (10 mL), dried
(MgSO4), ﬁltered, and the solvent removed under vacuum. The res-
idue was puriﬁed by chromatography using 5% EtOAc in heptane to
yield 39 as a yellow semi-solid. Yield: 62 mg, 47%. 1H NMR
(360 MHz, CDCl3) d ppm: 7.64 (1H, d, J = 8.2 Hz), 7.27–7.33 (2H,
m), 7.15 (2H, d, J = 8.6 Hz), 7.01 (1H, s), 6.81 (2H, d, J = 8.6 Hz),
5.17 (2H, s), 3.72 (3H, s), 2.77–2.84 (2H, m), 2.60–2.67 (2H, m).
LCMS: tR = 2.50 min, 369 (M+H)+ calcd for C19H17BrN2O.
4.1.7.7. 1-(4-Methoxy-benzyl)-7-(4,4,5,5-tetramethyl-[1,3,2]dio-
xaborolan-2-yl)-4,5-dihydro-1H-benzo[g]indazole (40). Stan-
dard boronylation procedure (as described for compound 26) using
intermediate 39 (62 mg, 0.17 mmol) resulted in the desired boro-
nic acid 40 (contaminated with 30% of the reduced material, 70%
corrected yield). This mixture was used in the next step without
further puriﬁcation. 1H NMR (250 MHz, CDCl3) d ppm: 7.82–7.90
(1H, m), 7.65–7.76 (2H, m), 7.24 (2H, d, J = 8.8 Hz), 7.08 (1H, s),
6.89 (2H, d, J = 8.7 Hz), 5.27 (2H, s), 3.81 (5H, s), 2.93 (2H, t,
J = 7.1 Hz), 2.72 (2H, t, J = 7.2 Hz), 1.36 (12H, s). LCMS:
tR = 2.62 min, 417 (M+H)+ calcd for C25H29BN2O.
4.1.7.8. 7-Bromo-1H-benzo[g]indazole (41). Compound 38
(170 mg, 0.68 mmol) was dissolved in dioxane (6 mL) and
DDQ (310 mg, 1.36 mmol) was added. The solution was re-
ﬂuxed for 3 h and the solvent was removed under vacuum.
2 M NaOH (10 mL) was added, and the aqueous layer was ex-
tracted with TBME (3  10 mL), dried (MgSO4) and the solvent
removed under vacuum. The residue was puriﬁed by chroma-
tography using a stepped gradient of 20–40% EtOAc in heptane
to yield 41 as red brick solid. Yield: 81 mg, 48%. 1H NMR
(250 MHz, CDCl3) d ppm: 8.10–8.18 (2H, m), 8.07 (1H, d,
J = 8.5 Hz), 7.67–7.78 (2H, m), 7.44 (1H, d, J = 8.5 Hz). LCMS:
tR = 1.96 min, 247 (M+H)+ calcd for C11H7BrN2.
4.1.7.9. 7-Bromo-1-(4-methoxy-benzyl)-1H-benzo[g]indazole
(42). NaH (60% in mineral oil, 8.6 mg, 0.36 mmol) was suspended
in DMF (2 mL) and 41 (81 mg, 0.33 mmol) was added in DMF
(1 mL). The suspension was stirred for 10 min and PMBCl (56 mg,
0.36 mmol) was added dropwise. The reaction was stirred at room
temperature for 1 h. Water (10 mL) was added and the aqueous
layer was extracted with TBME (3  10 mL). The organic layer
was washed with water (2  10 mL) and brine (10 mL), dried
(MgSO4), ﬁltered, and the solvent removed under vacuum. The res-
idue was puriﬁed by chromatography using 10% EtOAc in heptane
to yield 42 as a yellow solid. Yield: 93 mg, 77%. 1H NMR (250 MHz,
CDCl3) d ppm: 8.47 (1H, d, J = 8.7 Hz), 7.96 (1H, d, J = 1.8 Hz), 7.81
(1H, s), 7.67 (1H, dd, J = 8.5, 2.0 Hz), 7.51 (1H, d, J = 9.0 Hz), 7.31
(1H, s), 6.91 (2H, d, J = 8.7 Hz), 5.57 (2H, s), 3.81 (3H, s). LCMS:
tR = 2.47 min, 367 (M+H)+ calcd for C19H15BrN2O.4.1.7.10. 1-(4-Methoxy-benzyl)-7-(4,4,5,5-tetramethyl-[1,3,2]di-
oxaborolan-2-yl)-1H-benzo[g]indazole (43). Standard boronyla-
tion procedure (as described for compound 26) using intermediate
42 (93 mg, 0.25 mmol) resulted in the desired boronic acid 43
(53 mg, 51%). 1H NMR (250 MHz, CDCl3) d ppm: 8.59 (1H, d,
J = 8.1 Hz), 8.31 (1H, s), 7.99 (1H, d, J = 6.9 Hz), 7.79 (1H, s), 7.36–
7.51 (2H, m), 7.31(2H, d), 6.91 (2H, d, J = 8.7 Hz), 5.59 (2H, s),
3.81 (3H, s), 1.41 (12H, s). LCMS: tR = 2.59 min, 415 (M+H)+ calcd
for C25H27BN2O.4.1.8. Synthesis of ﬁnal compounds 1a–1p
4.1.8.1. Dimethyl-[2-(4-{5-[4-(1H-pyrazol-3-yl)-phenyl]-4-pyri-
din-4-yl-1H-imidazol-2-yl}-phenoxy)-ethyl]-amine (1a). {2-[4-
(5-{4-[1-(4-Methoxy-benzyl)-1H-pyrazol-3-yl]-phenyl}-1-methoxy-
methyl-4-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimeth-
yl-amine 8a (47 mg; 0.077 mmol) and anisole (17 lL; 0.153 mmol)
were dissolved in TFA (1.5 mL) and heated at 130 C for 4 h then
cooled to room temperature overnight. The solvent was evapo-
rated, the residue washed with TBME and puriﬁed by preparative
LC to give the desired compound (11 mg; 32%). 1H NMR
(360 MHz, MeOH) d ppm: 8.65 (2H, d, J = 5.4 Hz), 8.20 (2H, d,
J = 6.4 Hz), 8.12 (2H, d, J = 9.1 Hz), 8.05 (2H, d, J = 8.2 Hz), 7.80
(1H, s), 7.72 (2H, d, J = 8.2 Hz), 7.26 (2H, d, J = 9.1 Hz), 6.85 (1H,
s), 4.47–4.54 (2H, m), 3.67–3.73 (2H, m), 3.06 (6H, s). LCMS:
tR = 2.36 min, 451 (M+H)+ calcd for C27H26N6O. HRMS: (M+H)+
calcd for C27H26N6O: 451.2246, found: 451.2235.
4.1.8.2. Dimethyl-[2-(4-{5-[4-(4-methyl-1H-pyrazol-3-yl)-phe-
nyl]-4-pyridin-4-yl-1H-imidazol-2-yl}-phenoxy)-ethyl]-amine
(1b). {2-[4-(5-{4-[1-(4-Methoxy-benzyl)-4-methyl-1H-pyrazol-3-
yl]-phenyl}-1-methoxy methyl-4-pyridin-4-yl-1H-imidazol-2-yl)-
phenoxy]-ethyl}-dimethyl-amine 8b (60 mg; 0.096 mmol) and
anisole (21 ll; 0.192 mmol) were dissolved in TFA (1.5 mL) and
heated at 130 C for 4 h then cooled to room temperature over-
night. The solvent was evaporated, the residue washed with TBME
and puriﬁed by preparative LC to give the desired compound
(8 mg; 18%). 1H NMR (250 MHz, acetone) d ppm: 11.80 (1H, br s),
8.56 (1H, d, J = 5.2 Hz), 8.46 (1H, d, J = 6.2 Hz), 8.08 (2H, d,
J = 8.8 Hz), 7.83 (1H, d, J = 8.4 Hz), 7.73 (1H, s), 7.63–7.66 (2H, m),
7.61 (1H, s), 7.56 (1H, s), 7.52 (1H, d, J = 5.9 Hz), 7.06 (2H, d,
J = 9.0 Hz), 4.16 (2H, t, J = 5.9 Hz), 2.70 (2H, t, J = 5.9 Hz), 2.30 (3H,
s), 2.28 (6H, s). LCMS: tR = 2.45 min, 465 (M+H)+ calcd for
C28H29N6O. HRMS: (M+H)+ calcd for C28H29N6O: 465.2403, found:
465.2400.
4.1.8.3. 3-(4-{2-[4-(2-Dimethylamino-ethoxy)-phenyl]-5-pyri-
din-4-yl-3H-imidazol-4-yl}-phenyl)-1H-pyrazole-4-carbonitrile
(1c). 3-(4-{2-[4-(2-Dimethylamino-ethoxy)-phenyl]-3-methoxy-
methyl-5-pyridin-4-yl-3H-imidazol-4-yl}-phenyl)-1-(4-methoxy-
benzyl)-1H-pyrazole-4-carbonitrile 8c (61 mg; 0.096 mmol) was
dissolved in TFA (1.2 mL) and heated at 70 C for 4 h then cooled
to room temperature overnight. The solvent was evaporated, the
residue washed with TBME and puriﬁed by preparative LC to give
the desired compound (10 mg; 22%). 1H NMR (250 MHz, acetone) d
ppm: 8.51 (2H, dd, J = 4.6, 1.5 Hz), 8.43 (1H, s), 8.07 (4H, dd), 7.75
(2H, d, J = 8.5 Hz), 7.61 (2H, dd, J = 4.6, 1.5 Hz), 7.06 (2H, d,
J = 9.0 Hz), 4.16 (2H, t, J = 5.9 Hz), 2.70 (2H, t, J = 5.9 Hz), 2.28 (6H,
s). LCMS: tR = 2.42 min, 476 (M+H)+ calcd for C28H25N7O. HRMS:
(M+H)+ calcd for C28H25N7O: 476.2199, found: 476.2194.
4.1.8.4. [2-(4-{5-[4-(4-Chloro-1H-pyrazol-3-yl)-phenyl]-4-pyri-
din-4-yl-1H-imidazol-2-yl}-phenoxy)-ethyl]-dimethyl-amine
(1d). {2-[4-(5-{4-[4-Chloro-1-(4-methoxy-benzyl)-1H-pyrazol-3-
yl]-phenyl}-4-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-di-
methyl-amine 9d (18 mg; 0.03 mmol) was dissolved in TFA
(0.5 mL) and heated at 65 C for 11 h then cooled to room temper-
ature overnight. The solvent was evaporated, the residue washed
with TBME to give the desired compound (19 mg; 76%). 1H NMR
(360 MHz, MeOH/ CDCl3) d ppm: 8.54 (2H, br s), 8.11 (2H, d,
J = 5.4 Hz), 8.04 (4 H, dd, J = 8.6, 2.7 Hz), 7.72 (1H, s), 7.66 (2H, d,
J = 8.2 Hz), 7.14 (2H, d, J = 9.1 Hz), 4.42 (2H, t), 3.61 (2H, t),
2.99 (6H, s). LCMS: tR = 2.55 min, 485 (M+H)+ calcd for C27H25Cl-
N6O. HRMS: (M+H)+ calcd for C27H25ClN6O: 485.1856, found:
485.1873.
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din-4-yl-1H-imidazol-2-yl]-phenoxy}-ethyl)-dimethyl-amine (1e).
[2-(4-{4-[1-(4-Methoxy-benzyl)-4,5-dihydro-1H-benzo[g]indazol-
7-yl]-1-methoxy methyl-5-pyridin-4-yl-1H-imidazol-2-yl}-phe-
noxy)-ethyl]-dimethyl-amine 8e (13 mg; 0.02 mmol) was dis-
solved in TFA (1.5 mL), and anisole (4.4 mg; 0.04 mmol) was added.
The solution was heated in a sealed vessel for 24 h. The solvent was
removed under vacuum and the residue puriﬁed by preparative
HPLC to yield the desired compound 1e. TFA salt as a yellow glue
(1 mg, 6%). 1H NMR (360 MHz, MeOD) d ppm: 8.58 (2H, d,
J = 6.4 Hz), 8.16 (2H, d, J = 6.8 Hz), 8.07 (2H, d, J = 9.1 Hz), 7.91
(1H, d, J = 8.2 Hz), 7.54 (2H, d, J = 5.0 Hz), 7.50 (1H, d, J =
7.3 Hz), 7.21 (2H, d, J = 9.1 Hz), 4.44–4.48 (2H, m), 3.63–3.68
(2H, m), 3.49–3.52 (1H, m), 3.10–3.13 (1H, m), 3.02 (6H, s),
2.83–2.89 (2H, m). LCMS: tR = 2.50 min, 477 (M+H)+ calcd for
C29H29N6O. HRMS: (M+H)+ calcd for C29H29N6O: 477.2403, found:
477.2400.
4.1.8.6. (2-{4-[4-(1H-Benzo[g]indazol-7-yl)-5-pyridin-4-yl-1H-imi-
dazol-2-yl]-phenoxy}-ethyl)-dimethyl-amine (1f). Using the same
procedure as for 1e, 1f was obtained from 8f (33 mg; crude). Yield:
5 mg (8% over two steps). 1H NMR (250 MHz, MeOD) d ppm: 8.52–
8.62 (3H, m), 8.27 (1H, d, J = 1.37 Hz), 8.22 (1H, s), 8.07–8.16 (4H,
m), 7.79–7.89 (2H, m), 7.60 (1H, d, J = 8.98 Hz), 7.23 (2H, d,
J = 8.98 Hz), 4.47 (2H, t), 3.66 (2H, t), 3.02 (s, 6H). LCMS:
tR = 2.33 min, 475 (M+H)+ calcd for C29H27N6O. HRMS: (M+H)+
calcd for C29H27N6O: 475.2246, found: 475.2244.
4.1.8.7. 7-{2-[4-(2-Dimethylamino-ethoxy)-phenyl]-5-pyridin-
4-yl-1H-imidazol-4-yl}-2,4,4a,5-tetrahydro-indeno[1,2-c]pyri-
dazin-3-one (1g). Using the same procedure as for 1e, 1g (2.4 mg,
47%) was obtained from 8g. 1H NMR (360 MHz, MeOD) d ppm: 8.57
(2H, br s), 8.05 (2H, d, J = 8.9 Hz), 8.01 (2H, br s), 7.85 (1H, d,
J = 7.9 Hz), 7.66 (1H, s), 7.56 (1H, d, J = 7.9 Hz), 7.20 (2H, d,
J = 8.9 Hz), 4.41–4.50 (2H, m), 3.61–3.69 (2H, m), 3.44–3.55 (1H,
m), 3.01 (6H, s), 2.79–2.94 (2H, m), 2.45 (1H, t, J = 16.3 Hz). LCMS:
tR = 2.19 min, 493 (M+H)+ calcd for C29H29N6O2. HRMS: (M+H)+
calcd for C29H29N6O2: 493.2352, found: 493.2347.
4.1.8.8. 6-{2-[4-(4-Methyl-piperazin-1-yl)-phenyl]-5-pyridin-
4-yl-3H-imidazol-4-yl}-2,4-dihydro-indeno[1,2-c]pyrazole (1j).
Ketone 16a (37.1 mg; 0.083 mmol) was dissolved in dry DMF
(0.5 mL) and tris(dimethylamine)methane (86 lL; 0.50 mmol)
was added, reaction was heated to 85 C, under N2 for 3 h. Solvents
were removed under vacuum and residue was dissolved in AcOH
(0.5 mL). Hydrazine hydrate (12 lL; 0.25 mmol) was added to the
reaction mixture and was then stirred overnight. Solvent was re-
moved under vacuum and residue was puriﬁed by Flash column
chromatography on silica gel, eluting the desired product in 10–
50% EtOH/dichloromethane (DCM) (6 mg; 15%). 1H NMR (250
MHz, MeOD) d ppm: 8.35 (2H, d, J = 8.1 Hz), 7.88 (2H, d,
J = 8.8 Hz), 7.70 (1H, d, J = 7.9 Hz), 7.59 (2H, s), 7.51 (1H, s), 7.43
(1H, d, J = 7.6 Hz), 7.07 (2H, d, J = 9.0 Hz), 3.25–3.67 (10H, m),
2.87 (3H, s). LCMS: tR = 1.11 min 474 (M+H)+ calcd for C29H28N7.
HRMS: (M+H)+ calcd for C29H28N7: 474.2406, found: 474.2399.4.1.8.9. (2-{4-[5-(2,4-Dihydro-indeno[1,2-c]pyrazol-6-yl)-4-pyri-
din-4-yl-1H-imidazol-2-yl]-phenoxy}-ethyl)-dimethyl-amine
(1h). Using the same procedure as for 1j from 16b (38 mg;
0.087 mmol) the desired 1h was obtained (26 mg; 65%). 1H NMR
(250 MHz, MeOD) d ppm: 8.32 (2H, br s), 7.84 (2H, d, J = 8.7 Hz),
7.33–7.71 (6H, m), 6.97 (2H, d, J = 8.8 Hz), 4.06 (2H, t, J = 5.4 Hz),
3.58 (2H, s), 2.70 (2H, br s), 2.26 (6H, s). LCMS: tR = 1.10 min, 463
(M+H)+ calcd for C28H27N6O. HRMS: (M+H)+ calcd for C28H27N6O:
463.2246, found: 463.2242.4.1.8.10. 6-(2-Piperidin-4-yl-5-pyridin-4-yl-3H-imidazol-4-yl)-
2,4-dihydro-indeno[1,2-c]pyrazole (1k). Using the same proce-
dure as for 1j from 16c (33 mg; 0.069 mmol), the tert-butoxycar-
bonyl (Boc)-protected version of 1k was obtained. The residue
was dissolved in DCM (5 mL) and 4 N HCl (0.09 mL) added. After
stirring at rt for 4 h, the solvents were evaporated under vacuum
and the residue triturated with diethyl ether to leave the desired
product as the HCl salt of 1k (33 mg; 100%). 1H NMR (250 MHz,
MeOD) d ppm: 8.83 (2H, br s), 8.20 (2H, br s), 8.07 (1H, s), 7.64–
8.02 (3H, m), 3.94 (2H, br s), 3.63 (4H, d, J = 14.3 Hz), 2.20–2.57
(5H, m). LCMS: tR = 0.93 min, 383 (M+H)+ calcd for C23H22N6.
HRMS: (M+H)+ calcd for C23H22N6: 383.1984, found: 383.1077.
4.1.8.11. (2-{4-[5-(3,8-Dihydro-indeno[1,2-d] [1,2,3]triazol-6-
yl)-4-pyridin-4-yl-1H-imidazol-2-yl]-phenoxy}-ethyl)-dimethyl-
amine (1i). To a solution of ketone 16b (55 mg; 0.144 mmol) in
1 mL of methoxyethanol/HCl concd (3:1) at 0 C was added tBuON-
O (30 lL; 0.29 mmol). The reaction was stirred at 0 C for 1 min
then more tBuONO (30 lL; 0.29 mmol) were added. The solution
was stirred for 30 min at 0 C. Slowly 2 mL of NaOH (2 M) were
added. The solution was extracted with EtOAc (5 mL). The solvent
was removed under vacuo and the oily residue was dissolved in
8 mL of ethylene glycol/KOH (85%) (10:1). Hydrazine hydrate
(800 mg; 16 mmol) was added and the solution was heated at
190 C for 2 h in a boiling tube. The reaction was allowed to cool
to room temperature, diluted with 5 mL of water and extracted
with DCM (10 mL). The aqueous layer was evaporated under vac-
uum. The residue was loaded on Ambersep (sulfonic acid) resin
(10 mL). The resin was washed with MeOH (3  10 mL), H2O
(10 mL), HCl (1 M, 5  10 mL) then cleaved with HCl (5 M,
5  10 mL). The fractions were evaporated under vacuum. The res-
idue was suspended in 10 mL IPA/EtOH (1:1), ﬁltered. The solvent
was removed under vacuum, the residue was puriﬁed by reverse
phase column chromatography (C18) eluting with MeOH to afford
1.9 mg of 1i (3%). 1H NMR (360 MHz, MeOD) d ppm: 8.56 (2H, br s),
8.03–8.10 (3H, m), 7.92 (1H, d, J = 7.7 Hz), 7.84 (1H, s), 7.65 (1H, d,
J = 7.7 Hz), 7.21 (2H, d, J = 9.1 Hz), 4.46 (2H, t, J = 10.0 Hz), 3.91 (2H,
s), 3.66 (2H, t, J = 10.0 Hz), 3.02 (6H, s) LCMS: tR = 2.30 min, 464
(M+H)+ calcd for C27H26N7O. HRMS: (M+H)+ calcd for C27H26N7O:
464.2199, found: 464.2193.
4.1.8.12. [4-(2,4-Dihydro-indeno[1,2-c]pyrazol-6-yl)-5-pyridin-
4-yl-furan-2-yl]-[4-(2-dimethylamino-ethyl)-piperazin-1-yl]-
methanone (1l). Ketone 22b (86 mg; 0.19 mmol) was dissolved
in dry DMF (1 mL) and DMF–DMA (112 mg; 0.94 mmol) was added.
The reactionwas heated to 85 C for 3 h. Solventwas removedunder
vacuum and remaining DMF was azeothroped with EtOH/heptane.
The residuewasdissolved inAcOH (1 mL) and thehydrazinehydrate
(45 lL; 0.94 mmol) was added. Reaction was stirred at room tem-
perature overnight. The reactionmixturewas basiﬁed to pH 11with
NH4OH (concd), extractedwith EtOAc (4  6 mL), dried (MgSO4) ﬁl-
tered and evaporated to dryness to leave a yellow solid. This solid
was dissolved in 1 M HCl (10 mL) and washed with EtOAc
(2  5 mL). Aqueous was basiﬁed with 2 M NaOH to pH 11 and ex-
tracted again with EtOAc, dried (MgSO4), ﬁltered and evaporated
to dryness to leave a cream solid. Yield: 20 mg (22%). 1H NMR
(360 MHz, MeOH) d ppm: 8.49 (2H, d, J = 7.5 Hz), 7.79 (1H, d,
J = 7.8 Hz), 7.55–7.66 (4H, m), 7.45 (1H, d, J = 7.8 Hz), 7.24 (1H, s),
3.94 (4H, br s), 3.70 (2H, s), 2.53–2.68 (8H, m), 2.32 (6H, s). LCMS:
tR = 1.16 min, 483 (M+H)+ calcd forC28H30N6O2.HRMS: (M+H)+ calcd
for C28H30N6O2: 483.2508, found: 483.2514.
4.1.8.13. [4-(2,4-Dihydro-indeno[1,2-c]pyrazol-6-yl)-5-pyridin-
4-yl-furan-2-yl]-morpholin-4-yl-methanone (1m). Starting from
ketone 22c (96 mg; 0.25 mmol) and using the same procedure as
for compound 1l the desired compound was obtained (18 mg;
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J = 7.8 Hz), 7.54–7.63 (4H, m), 7.44 (1H, dd, J = 7.9, 1.4 Hz), 7.26
(1H, s), 3.91 (4H, br s), 3.75–3.84 (4H, m), 3.71 (2H, s). LCMS:
tR = 3.03 min, 413 (M+H)+ calcd for C24H21N4O3. HRMS: (M+H)+
calcd for C24H21N4O3: 413.1614, found: 413.1611.
4.1.8.14. 4-[4-(2,4-Dihydro-indeno[1,2-c]pyrazol-6-yl)-5-pyri-
din-4-yl-furan-2-carbonyl]-piperazine-1-carboxylic acid tert-
butyl ester (23d). Starting from ketone 22d (106 mg; 0.22 mmol)
and using the same procedure as for compound 1l the desired com-
pound was obtained (70 mg; 63%). 1H NMR (250 MHz, CDCl3-d) d
ppm: 8.53 (2H, br s), 7.81 (1H, d, J = 7.8 Hz), 7.45–7.57 (2H, m),
7.32–7.45 (3H, m), 7.18 (1H, s), 3.87 (4H, br s), 3.65–3.72 (2H,
m), 3.49–3.64 (4H, m), 1.48 (9H, s). LCMS: tR = 3.62 min, (M+H)+
calcd for C29H29N5O4.
4.1.8.15. [4-(2,4-Dihydro-indeno[1,2-c]pyrazol-6-yl)-5-pyridin-
4-yl-furan-2-yl]-piperazin-1-yl-methanone (1n). BOC amide
23d was dissolved in DCM (0.5 mL) and dioxane (0.3 ml) and 4 N
HCl in dioxane (0.3 mL) was added. After stirring at room temper-
ature for 2 h, the solvents were evaporated under vacuum to leave
the desired 1n (30 mg; 100%). 1H NMR (250 MHz, MeOD) d ppm:
8.74 (2H, d, J = 6.1 Hz), 8.16 (2H, d, J = 6.3 Hz), 8.08 (1H, s), 7.96
(1H, d, J = 7.8 Hz), 7.87 (1H, s), 7.68 (1H, d, J = 7.9 Hz), 7.47 (1H,
s), 4.00–4.37 (4H, m), 3.86–3.98 (2H, m), 3.36–3.52 (4H, m). LCMS:
tR = 2.45 min, 412 (M+H)+ calcd for C24H22N5O2. HRMS: (M+H)+
calcd for C24H22N5O2: 412.1774, found: 412.1769.
4.1.8.16. [4-(2,4-Dihydro-indeno[1,2-c]pyrazol-6-yl)-5-pyridin-
4-yl-furan-2-yl]-(4-methyl-piperazin-1-yl)-methanone (1o). Start-
ing from ketone 22a (79 mg; 0.20 mmol) and using the same pro-
cedure the desired compound was obtained (50 mg; 60%). 1H NMR
(250 MHz, MeOD) d ppm: 8.47 (2H, br s), 7.77 (1H, d, J = 7.8 Hz),
7.48–7.67 (4H, m), 7.43 (1H, d, J = 7.6 Hz), 7.22 (1H, s), 3.73–4.11
(4H, m), 3.68 (2H, s), 2.45–2.70 (4H, m), 2.36 (3H, s). LCMS:
tR = 2.41 min, 426 (M+H)+ calcd for C25H23N5O2. HRMS: (M+H)+
calcd for C25H23N5O2: 426.1930, found: 426.1934.
4.1.8.17. [4-(2-Dimethylamino-ethyl)-piperazin-1-yl]-[4-(1-met
hyl-1,4-dihydro-indeno [1,2-c]pyrazol-6-yl)-5-pyridin-4-yl-fur
an-2-yl]-methanone (1p). The starting ketone 22b (34 mg,
0.07 mmol) was dissolved in dry DMF (0.5 mL) and DMFDMA
(44 mg; 0.37 mmol) was added. The reaction was stirred for
90 min. The solvents were removed under vacuum and the residue
azeotroped with heptane. The crude was then dissolved in AcOH
(0.5 mL) and treated with methylhydrazine (51 mg; 1.11 mmol).
The reaction was stirred at room temperature for two days, upon
which concentrated NH4OH solution was added to pH 11. NaHCO3
saturated solution (10 mL) was added and the aqueous layer was
extracted with EtOAc (3  10 mL), dried (MgSO4) and the solvent
removed under vacuum. The residue was puriﬁed by chromatogra-
phy using a stepped gradient of 0–15% MeOH in DCM. The product
was re-suspended in EtOAc (2 mL) and washed with water
(5  1 mL). The organic layer was dried (MgSO4) and the solvent
removed in vacuo to yield a pale yellow glue (3 mg; 8%). 1H NMR
(250 MHz, MeOD) d ppm: 8.46–8.52 (2H, m), 7.80 (1H, d), 7.64
(1H, s), 7.54–7.60 (2H, m), 7.45–7.52 (1H, m), 7.43 (1H, s), 7.25
(1H, s), 4.15 (3H, s), 3.91 (4H, br s), 3.64 (2H, s), 2.58–2.67 (8H,
m), 2.34 (6H, s). LCMS: tR = 2.73 min, 497 (M+H)+ calcd for
C29H33N6O2. HRMS: (M+H)+ calcd for C29H33N6O2: 497.2665,
found: 497.2660.
4.2. Docking and modelling
Inhibitor 1a was docked using GOLD version 3.1.1[5] on the
crystal structure of BRAF in complex with SB590885 [PDB 2FB8].Partial charges of the ligand were derived using the Charge-2 CORI-
NA 3D package in TSAR 3.3, and its geometry optimized using the
COSMICmodule of TSAR. The calculationswere terminated if the en-
ergydifferenceor the energygradientwere smaller than1E-005. Ten
docking solutions were generated, and the best three stored for
analysis.
4.3. Biology
4.3.1. V600EBRAF kinase assay and SRB IC50 for BRAF inhibitors
These assays have been described by Niculescu-Duvaz et al.15
4.3.2. Phospho-ERK IC50 assay
To determine the effect of compounds on BRAF activity in
cells, WM266.4 cells were seeded at a density of 3  104 cells
per well of a 96 well plate. The following day, test compounds
were diluted into growth medium to 2 the desired ﬁnal con-
centration and then added directly to the cells. After a 6 h incu-
bation, the medium was removed and cells were ﬁxed and
permeabilized in 4% formaldehyde, 0.1% triton X-100 in PBS for
30 min. The wells were then blocked with 5% milk in PBS for
30 min at room temperature, followed by the addition of an anti-
body for phospho-ERK1/2 (Sigma, Dorset, UK) at 3 mg/ml in
blocking solution. Plates were incubated for 3 h with shaking.
Plates were washed three times with 0.1% Tween 20 using an
ELx50 plate washer (BioTek, Winooski, USA). 0.5 mg/ml of a
Europium-labelled anti-mouse secondary antibody (Perkin Elmer,
Turku, Finland) was added to the wells in DELFIA assay buffer for
1 h. Plates were washed again and Enhancement solution was
added to the wells and time resolved ﬂuorescence was measured
as instructed by the manufacturer after 20 min using a Spectra-
max M5 plate reader (Molecular Devices, Berkshire, UK). The
plates were washed again and BCA protein assay reagent (Sigma,
Dorset, UK) was added to the wells and incubated for 30 min at
37 C. Absorbance at 570 nm was measured using a plate reader
and used to normalize the ﬂuorescence data. Inhibition of ERK
phosphorylation was determined as a percentage of DMSO-trea-
ted cells and IC50 values were calculated using Prism (GraphPad
Software, San Diego, USA).
4.3.3. PK assessment
Female Crl:CD1-Foxn1nu mice at least six weeks of age bearing
mutant BRAFWM266.4 human tumor xenografts were used for the
PK analyses. The mice were dosed intraperitoneally (4 mg/kg,
equivalent to ca. 8 lmol/kg, 10 ml/kg, in 10% ethanol:40%
PEG:50% Gelofusine v/v) in a cassette with 4 other compounds.
Samples were taken at 8 time-points between 15 min and 24 h.
Three mice were utilized per time-point. They were placed under
isoﬂurane anaesthesia and blood for plasma preparation was taken
by terminal cardiac puncture into heparinized syringes. Plasma
samples were snap frozen in liquid nitrogen and then stored at
70 C prior to analysis. All procedures involving animals were
performed in accordance with national Home Ofﬁce regulations
under the Animals (Scientiﬁc Procedures) Act 1986 and within
guidelines set out by the Institute’s Animal Ethics Committee and
the United Kingdom Coordinating Committee for Cancer Research’s
ad hoc Committee on the Welfare of Animals in Experimental
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